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Women, who abuse drugs during pregnancy, expose not just themselves but also their 
developing foetus to impairing effects, which can have potentially harmful and even long-term 
effects on the exposed children. For some years, methamphetamine (MA) has dominated the 
illicit drug market in the Czech Republic and Slovakia; additionally this drug is on the rise 
worldwide. It is one of the most accessible drugs, and in many cases the first choice drug for 
many drug-addicted pregnant women; in part due to its anorectic and stimulant effects. These 
women are rarely aware of the consequences of their behaviour and their pregnancy is hardly 
ever a good enough reason for giving up drug use.  
These findings are supported by many experimental studies that show the damaging 
effects of maternal MA exposure on their offspring. There is growing evidence that exposure 
to MA in utero not only causes birth defects and delays in infant development, but also impairs 
the brain reward neural pathways of a developing offspring in such a way, that it could increase 
the predisposition for drug addiction later in life. Previously published animal studies have 
shown that offspring of mothers exposed to MA during pregnancy are more sensitive to MA 
when they encounter this drug later in adulthood. With respect to increased sensitivity, the term 
of behavioural sensitisation (BS) has been introduced. It is defined as augmented psychomotor 
activity, which can be observed after drug re-administration following discontinuation of 
repeated drug exposure, and has been demonstrated to develop not only after repeated drug 
administration in adulthood, but also after chronic prenatal exposure.  
The aim of my PhD thesis was to determine if prenatal MA exposure can cause cross-
sensitisation to different drugs administrated in adulthood.  
Pregnant dams were injected daily with MA (at a dose of 5 mg/kg) or saline 
subcutaneously (s. c.) over the entire length of the gestation period. To test the sensitivity after 
prenatal exposure, rats were administered s. c. with (a) the same drug (MA), (b) drugs with the 
same mechanism of action to MA (amphetamine- AMP, cocaine- COC, MDMA), or (c) drugs 
with different mechanisms of action (morphine- MOR, delta9-tetrahydrocannabinol- THC). 
The dose of the drug administered as well as the regimen of administration depended on the 
behavioural test used. In adulthood, males and females rats were tested using five different test 
situations. Conventionally, the Conditioned Place Preference (CPP) and the Laboras test are 
used for testing BS. Firstly, active drug-seeking behaviour tested using the CPP is thought to 
be a model of cue-induced craving seen in human addicts. Secondly, enhanced locomotor 
activity as seen in the Laboras test (after a single drug injection) models drug-induced 




shown to affect various forms of behaviour as well as cognition, the following tests were also 
used: the Elevated Plus Maze test (EPM) for testing anxiety, the Morris Water Maze test 
(MWM) for testing spatial learning and memory, and the Social Interaction test (SIT) for testing 
social behaviour in male rats only. In adult female rats, phases of the oestrous cycle were 
observed and compared. 
Our results showed that there was a sensitising effect that could be attributed to prenatal 
MA exposure to other drug treatment in adulthood, which was best demonstrated using the 
spontaneous locomotor activity component of the Laboras test. Specifically, increased 
locomotion after prenatal MA exposure was found in females and males with an adult AMP 
treatment, and in females with adult COC and MDMA treatment. There was no interaction 
between prenatal MA exposure and adult drug treatment observed using the CPP test, so that it 
seems that in utero MA exposure does not cause changes that could increase drug-seeking 
behaviour later in adulthood. Interestingly, prenatal MA exposure sensitised male rats to the 
social interaction-decreasing effect of MA, AMP, and MDMA.  
As far as other tests were concerned, the study found sex differences with regard to 
various drugs in behaviour and cognition. It seems that in some test situations and adult drug 
treatment, females were more sensitive than males. Based on sex differences we observed the 
following: (1) In the EPM test, MA, AMP, and COC induced anxiolytic-like effect, but only in 
females, while MDMA induced anxiogenic-like effects. (2) In the MWM, chronic treatment 
with MA, AMP, COC, MDMA, MOR, and THC lowered learning abilities and memory recall 
in female rats. (3) Additionally, female memory recall was shown to be worse in contrast to 
males, regardless of the adult drug treatment; (4) moreover, females relative to males 
demonstrated increased locomotion and decreased anxiety, especially in the phase of 
proestrus/oestrus when hormone levels were high.  
In conclusion, our study showed that prenatal MA exposure can influence the sensitivity 
to the effects of some drugs, given as a challenge, in adulthood, specifically to those with a 
similar action mechanism. Our findings indicate that cross-sensitisation between prenatal MA 
exposure and adult drug treatment cannot be simply termed as a general drug addiction, since 
it seems that the mechanism by which a drug impairs specific neurotransmitter systems plays 
an important role. The study findings show that although the offspring of MA-addicted mothers 
have altered sensitivity to certain drugs in adulthood, they do not display increased active drug-
seeking behaviour. Therefore, if we extrapolate the results to humans, it appears that there is a 
relatively little risk that a person, whose mother abused MA during pregnancy, will actively 





Na drogách závislé těhotné ženy vystavují negativním účinkům drog nejen sebe, ale i 
své vyvíjející se potomky, což je může dlouhodobě negativně ovlivnit. Už několik let dominuje 
metamfetamin (MA) drogovému trhu jak v České republice, tak na Slovensku, avšak stále 
rostoucí je i jeho spotřeba celosvětově. Je stále jednou z nejvíce dostupných drog, a v mnohých 
případech drogou první volby pro těhotné ženy závislé na drogách, kvůli jeho anorexigennímu 
a únavu potlačujícímu účinku. Tyto ženy jsou si zřídkakdy vědomy důsledků svého chování, a 
jejich těhotenství je pro ně málokdy důvodem k ukončení užívání drog.  
Tato zjištění byla potvrzena celou řadou experimentálních studií sledujících vliv 
mateřské aplikace MA na potomstvo. Stále rostoucí počet studií poukazuje na fakt, že vystavení 
MA in utero nezpůsobuje jenom vývojové vady a poruchy ve vývoji centrálního nervového 
systému, ale může vést k takovým změnám ve vyvíjejícím se systému odměny mozku, které 
zvýší pravděpodobnost k rozvoji drogové závislosti později v životě. Dostupné studie na 
animálních modelech poukázaly na fakt, že potomci matek, kteří byli vystaveni prenatálně 
účinkům MA, jsou citlivější k aplikaci MA v dospělosti. Pro zvýšenou sensitivitu na účinky 
drogy byl zaveden termín behaviorální senzitizace (BS). BS je definována jako zvýšená 
psychomotorická aktivita po jednorázové aplikaci drogy, když dříve došlo k návyku na tuto 
drogu. BS byla pozorována nejen po opakovaném podávání drogy v dospělosti, ale také po 
chronické prenatální expozici účinkům drogy.  
Cílem této dizertační práce bylo otestovat vliv prenatální expozice MA na vznik 
zkřížené citlivosti k různým drogám aplikovaným v dospělosti.  
Dospělým samicím laboratorního potkana byl po celou dobu březosti aplikován 
subkutánně (s. c.) MA (v dávce 5 mg/kg/den) nebo fyziologický roztok. Abychom otestovali 
citlivost dospělých potomků po prenatální expozici, zvířatům byla aplikována s. c. (a) stejná 
droga (MA), (b) příbuzné drogy (amfetamin-AMP, kokain-COC, MDMA), (c) nepříbuzné 
drogy (morfin-MOR, THC). Dávka aplikované drogy, jako i systém dávkování závisel na 
použitém behaviorálním testu. V dospělosti, samci a samice byli testováni v pěti různých 
behaviorálních testech. Tradičně, test aktivního vyhledávání drog („Conditioned place 
preference“ - CPP) a test na spontánní lokomoční aktivitu v neznámém prostředí (Test Laboras) 
jsou používány k testování BS. Zaprvé, aktivní vyhledávání drogy v CPP testu je považováno 
za model podmiňovaného bažení po droze u závislých jedinců. Zadruhé, zvýšená lokomoční 
aktivita v testu Laboras modeluje situaci drogou zvýšené hyperaktivity a euforie. Protože 
aplikace drog ovlivňuje různé formy chování a taky kognitivní schopnosti, použili jsme v naší 




vodní bludiště- MWM, k testování prostorového učení a paměti, a Test sociální interakce- SIT, 
k testování vzájemných sociálních interakcí jenom u samců. Byly zjišťovány případné pohlavní 
rozdíly a vliv ženských pohlavních hormonů v různých fázích estrálního cyklu na měřené 
parametry u jednotlivých experimentů. 
Naše výsledky ukázaly, že prenatální expozice MA zvýšila citlivost k některým drogám 
aplikovaným v dospělosti, což bylo zejména pozorováno na spontánní lokomoční aktivitě 
v testu Laboras. Konkrétně, zvýšená lokomoce po prenatální expozici MA byla zjištěna u 
samců a samic s akutní aplikací AMP, a u samic s akutní aplikací COC a MDMA. V testu CPP 
nebyla zjištěna interakce mezi prenatální aplikací MA a aplikací ostatních drog v dospělosti. 
Zdá se tedy, že vystavení MA in utero nezpůsobuje takové změny, které by zvýšily zájem o 
vyhledávání drogy v dospělosti.  
Pokud se ostatních testů týká, naše studie demonstrovala pohlavní rozdíly v účinku 
různých drog na chování a kognitivní schopnosti. Ukázalo se, že za určitých testovacích 
podmínek byly samice citlivější k akutní nebo chronické aplikaci drogy v dospělosti nežli 
samci. Konkrétně, v testu EPM, MA, AMP a COC měly anxiolytický účinek, ale pouze u samic, 
zatímco MDMA měl účinek anxiogenní. Chronická aplikace MA, AMP, COC, MDMA, MOR 
a THC zhoršila schopnost učení a vybavitelnost paměťové stopy u samic. Navíc, prostorové 
učení bylo horší u samic a to nezávisle na aplikaci drogy. Pozorovali jsme také zvýšenou 
lokomoci a sníženou anxietu u samic v porovnání se samci, a to zvláště ve  fázi proestrus/estrus 
s vysokou hladinou pohlavních hormonů.  
Výsledky této dizertační práce ukazují, že prenatální expozice MA zvyšuje citlivost 
k účinku aplikace drog v dospělosti, konkrétně k těm s podobným mechanizmem účinku. 
Avšak, naše výsledky naznačují, že vznik zkřížené citlivosti mezi prenatálním MA a akutní 
aplikací drogy nemůže být chápán jako vznik obecné závislosti. Zdá se, že mechanizmus účinku 
drogy na neurotransmiterové systémy sehrává pravděpodobně klíčovou roli ve 
vzniku senzitizace. Nadějným je zjištění, že potomci matek závislých na MA mají sice 
změněnou citlivost k drogám v dospělosti, ale neprojevují zvýšený zájem o jejich aktivní 
vyhledávání. Takže pravděpodobnost, že by osoba, jejíž matka užívala MA během těhotenství, 
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I. INTRODUCTION  
1 THE CURRENT SITUATION REGARDING DRUG ABUSE  
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defined 
‘high risk drug use’ as injecting drugs use or long duration/regular use of opioids, cocaine 
and/or amphetamines. This definition specifically includes regular or long-term use of 
prescribed opioids such as methadone but excludes their rare or irregular use and the use of 
other drugs, such as ecstasy or cannabis. Globally, it is estimated that 246 million people 
between the ages 15 and 64 (that is 1 out of 20) used any kind of illicit drug in 2013. According 
to the most recent data available, by estimation 12.2 million out of these people injected drugs 
(World Drug Report 2015). In Eastern and South-eastern Europe from 1.8 to 4.8 million of 
people injected some illicit drug in 2013. Based on the annual statistics, the top four most 
misused illicit drugs in 2013 globally were cannabinoids (with 181 million users), opioids (32.4 
million users), cocaine (17 million users), ecstasy (18.8 million users) and amphetamine-types 
stimulants (33.9 million users). Because of the increasing availability of methamphetamine in 
some markets the use of methamphetamine has continued to rise since 2012 (World Drug 
Report 2015). Globally, the number of amphetamine-type drug laboratories (including 
methamphetamine) that were dismantled increased from 12 571 in 2011 to 14 322 in 2012. The 
increase in amphetamine-type drug seizures from 2002 is primarily attributable to the growing 
amount of methamphetamine seized, which increased from 34 tons in 2009 to 88 tons in 2013 
(World Drug Report 2015). In 2012, methamphetamine accounted for 114 tons of a total 144 
tons of amphetamine type drug seizures (World Drug Report 2014). 
For some years, methamphetamine has dominated the market in the Czech Republic and 
Slovakia. However, in 2013, methamphetamine seizures not only accounted for the largest 
share of amphetamine-types substance seizures reported in the Czech Republic and Slovakia, 
but also in some countries in the Baltics and Eastern Europe, such as Belarus, Latvia, Lithuania 
and in addition Greece and Portugal (World Drug Report 2015). Two main European areas of 
methamphetamine production can be identified. The first one is in the Baltic States, which 
mainly export to Norway and to the United Kingdom. In this region benzyl methyl ketone is 
used as a principal precursor. In the second area, around the Czech Republic, Slovakia and 
Germany, production of methamphetamine, known also as pervitin, is mainly based on 
ephedrine and pseudoephedrine, and takes place in small-scale so-called kitchen laboratories, 
and from here the output is destined primarily for distribution within these countries (European 




the Czech Republic. After the introduction of restrictions on the sale of medicines containing 
pseudoephedrine in the Czech Republic in 2009, an increase in imports of other pharmaceutical 
products from neighbouring countries has been reported, mainly from Poland. A new 
production method has been reported from Serbia, where ephedrine and pseudoephedrine are 
produced from L-PAC (phenylacetylcarbinol) (Exploring methamphetamine trends in Europe 
2015).  
The Annual Report on the Drug Situation in the Czech Republic (2013) stated that the 
four most abused drugs in the population of people aged 15-64 are cannabinoids, ecstasy, 
hallucinogenic mushrooms (e.g., Psilocybe bohemica, Psilocybe semilanceata and others) and 
methamphetamine. In 2013, 261 small kitchen laboratories were found in the Czech Republic 
and 69.1 kg of methamphetamine seizures was reported the same year. This number represents 
a twofold increase since 2012. It has been estimated that there were 44.9 thousand of ‘high risk 
drug users’ in 2013, out of those 34.2 thousand used methamphetamine. As far as the regional 
differences are concerned, an increase in the number of high risk methamphetamine users was 
reported in Prague, Central and South Bohemian Region, Liberec and Vysočina Region (2013  
Annual Report: the Czech Republic Drug Situation 2013). It has also been shown that young 
Czechs underestimate the risks connected to drug use more than young people from other 
European countries (European Drug Report 2015).  
Another growing problem of recent years is of drug abuse during pregnancy. Women 
using drugs during pregnancy expose not just themselves but also their developing foetus to the 
substance and this can have potentially harmful and long-term effects on the exposed children. 
Over the past several years the number of infants with drug-related birth defects has increased 
dramatically. Almost half of women of a reproductive age, who take drugs, replace another 
drug with methamphetamine during pregnancy. The reasons they do so is, because this drug 
has an anorectic effect, as well as providing an increase in alertness (Marwick 2000). Moreover, 
it is difficult to reason with drug-addicted woman, as their pregnancy is hardly ever a reason 
for giving up drug use. In addition to drug use, drug abusing pregnant women often consume 
alcohol and smoke cigarettes. Bad social conditions including unemployment and prostitution 
are also common problems which worsen their life situation (Vavříková et al. 2001).  
It is clear from this data that the research of harmful effects which can be caused by 
methamphetamine abuse deserves some attention. Although many studies examining the effects 
of methamphetamine administration during pregnancy have been reported, findings from this 




2 THE DRIVING FORCE FOR TAKING DRUGS 
Drug addiction is a relapsing disorder in which compulsive drug-seeking and drug-
taking persist despite serious negative consequences (Koob and Moal 2006a). What plays the 
key role in the process of a drug dependence development has always been discussed. One of 
the most important findings for understanding the motivation of drug users in general, was made 
in 1954 by James Olds and Peter Milner. They used the intracranial electrical stimulation of the 
hypothalamus and associated structures and found out that this stimulation can act as a 
reinforcement of reward for behaviour. The discovered reward pathway is an evolutionary old 
and stable system, which is essential for survival (Kupfermann et al. 2000). The key role of this 
system is to find out important reinforcing stimuli, associate it with some value, predict a 
reward's response and initiate a motivational reply which leads to some kind of behaviour 
resulting in feelings of satisfaction and reward. The previously mentioned brain stimulations in 
that experiment act in many respects like natural reinforcers, but with one important difference. 
While natural reinforcers are effective only if the animal is in a particular drive state (e.g. 
searching for food is reinforced in a hungry animal), electrical stimulation of the brain works 
regardless of the animal's drive state. While in the experiments of Olds and Milner an electrical 
stimulation made an animal pull a lever more frequently, in the life of an addicted person, the 
pleasure after taking drugs and the craving without that drug drives him to search for it. A 
feeling of satisfaction after taking a drug arises more quickly and with a higher intensity than 
the pleasure which arrives after natural reinforcers (Kupfermann et al. 2000).  
Imaging studies have provided evidence that multiple brain circuits are involved in the 
development of addiction. These circuits are connected to one another by direct or indirect 
innervations that are either glutamatergic (GLU) or GABAergic (Volkow et al. 2004). The 
fundamental role in the reward system is played by dopamine (DA) - the predominant 
catecholamine neurotransmitter (NT) in the brain, which is synthesized by mesencephalic 
neurons in the substantia nigra (SN) and the ventral tegmental area (VTA). The neurons of VTA 
form most of the mesolimbic and mesocortical projections involved in the reward pathway (see 
Fig. 1). It has been demonstrated that drugs of abuse induce large increases in DA in the nucleus 
accumbens (NAc) and the prefrontal cortex (PFC) (Koob and Bloom 1988, Shoblock et al. 
2003a) and this DA increase is linked to the reinforcing effects of stimulants as assessed by the 
subjective reports of “high” and “euphoria” in addicted as well as non-addicted subjects 
(Volkow et al. 2004). Additionally, a lower level of D2 receptors in the striatum in a wide 




addicts less sensitive to natural reinforces and thus give them a higher predisposition to drug 
addiction (Volkow et al. 2004).  
While the mesolimbic reward pathway (the VTA to core of the NAc) is necessary for 
the ‘pleasure principle’ of drug taking, the development of drug addiction cannot be fully 
understood without looking beyond this principle. The repeated stimulation of the shell of the 
NAc activates the NAc core, which is connected to the dorsal striatum (nucleus caudatus and 
putamen) and leads to an increase in synaptic plasticity and shifts from recreational drug taking 
to uncontrolled behaviour and compulsive drug searching. At this time, PFC regions including 
the orbitofrontal cortex (OFC) and the anterior cingulate gyrus, which are connected to decision 
making and emotions, get involved. The OFC plays an important role in attributing salience to 
rewards (Everitt and Robbins 2005) (Fig. 1). Decreased activity of these brain areas has been 
documented to affect the motivational process and to lead to a loss of control over the drug use 
of an addicted person (Volkow et al. 2001a, Volkow et al. 2001b). 
It is also well known that the drug effects are modulated by non-pharmacological 
variables like a subject's expectation of the effects of a drug, which in turn modify responses to 
the drug. It was shown in the positron emission tomography studies (PET) that in the brains of 
subjects who received methylphenidate intravenously, the DA concentration in mediodorsal 
and paraventricular nuclei of thalami was 50 % higher when people were expecting the drug. 
The thalamus receives direct projections from DA cells and from the OFC and also indirect 
projections from the NAc, and sends projections back to these regions, forming cortico-striatal-
thalamic loops, through which thalamus modulates the drug response by expectations (Deutch 
et al. 1998). Also limbic regions (e.g. amygdala, ventral striatum, and ventral cingulate) and 
multiple memory systems are traditionally linked to reinforcing stimuli. Additionally, 
conditioned-incentive learning (mediated in part by the NAc and the amygdale), habit learning 
(mediated by the caudate and putamen) and declarative memory (by hippocampus) contribute 






Figure 1: Cortico-striatal-thalamic loop involved in drug addiction. VTA- ventral 
tegmental area, SNc- substantia nigra pars compacta, Acb shell- shell of nucleus accumbens, 
Acb core- core of nucleus accumbens, VGP- ventral globus pallidus, DGP- dorsal globus 
pallidus, BLA- basolateral complex of amygdala, CeN- central nucleus of amygdala. Narrows 
indicate neurotransmitter systems: green- glutamatergic; red- dopaminergic; pink- GABAergic. 
From: Everitt and Robbins (2005). 
 
3 AN OVERVIEW OF PSYCHOSTIMULANT TYPES OF DRUGS 
3.1 AMPHETAMINES TYPE OF DRUGS 
Amphetamine type drugs are produced by a chemical synthesis and can be divided into 
two categories: legal amphetamine derivatives (methamphetamine- MA, amphetamine- AMP 
and its isomers and analogues- ephedrine, phenmetrazine, methylphenidate, phentermine and 
chlorphentermine) and illegal amphetamine derivatives (MDMA= N-methyl-3,4-






MA is one of the most widely abused amphetamine type drugs worldwide, including the 
Czech Republic (Marwick 2000, Vavřínková et al. 2001). The main reason for its popularity is 
because of its relatively uncomplicated production and low price when compared to other 
psychostimulants (Marwick 2000).  
 
3.1.1.1 PHARMACOKINETICS AND PHARMACODYNAMICS OF 
METHAMPHETAMINE 
MA is a powerful addictive psychostimulant drug with a high potential for addiction, 
which exists in two forms: base and salt. The pure base is a clear, volatile oil, which is insoluble 
in water and can be readily converted into MA hydrochloride (the most prominent salt form). 
The hydrochloride salt form is a crystalline solid, which is soluble in water. In powder form 
MA granulated crystals can be mixed with other ingredients such as lactose, dextrose or 
caffeine. Powder MA is either inhaled intra-nasally (snorted) or dissolved and injected. The 
MA euphoric effect lasts for a long time (from 8 to 24 hours) because of the slow drug 
metabolism. Bioavailability, the time to the peak effect and the time to reach peak plasma 
concentration, differ based on the route of administration (Cruickshank and Dyer 2009), with 
the terminal plasma half-life of MA being approximately 10 hours. It has got a high 
bioavailability: 62.7% after oral, 79% after nasal, 90% after smoking, and 100% after 
intravenous administration. The metabolism of MA largely takes place in the liver via a) N-
demethylation to produce AMP (catalysed by cytochrome P450 2D6); b) aromatic 
hydroxylation (via cytochrome P450 2D6) producing 4-hydroxymethamphetamine; and c) beta-
hydroxylation to produce norepinephrine. Inter-individual variability in MA metabolism might 
involve the polymorphic cytochrome P450 2D6 (Lin et al. 1997). Approximately 70% of MA 
leaves the body via urine within 24 hours (30-50% as MA, 10% as AMP and up to 15% as 4-
hydroxymethamphetamine (Bečková and Višňovský 1999a, Harris et al. 2003). 
MA is an indirect agonist at DA, noradrenaline (NA) and serotonin (5-HT) receptors. 
Its main action is to increase the concentration of these three NT. Thanks to its structural 
similarity, MA substitutes for monoamines in two places: a) cell surface integral membrane 
proteins-transporters, namely the DA transporter (DAT), the NA transporter (NET) and the 
serotonin transporter (SERT); and b) vesicular monoamine transporters (VMAT 2). 
Physiologically, membrane transporters help to pump the amines back to the synapse, where 




In vitro studies showed that MA is twice as potent at releasing NA as DA, and has a 60 times 
greater effect on a NA than a 5-HT release (Rothman and Baumann 2003). MA's effect on NTs 
overflow is primarily due to a reverse transport of them from the cytosol into the synapse, and 
the uptake inhibition also contributes to the total effect (Sulzer et al. 2005). As far as the storage 
of the NTs in the presynaptic terminals is concerned, MA redistributes monoamines from 
storage vesicles into the cytosol by reversing the function of VMAT 2, and also by disturbing 
the pH gradient which normally drives the accumulation of monoamines in the vesicles. With 
the help of these two mechanisms, monoamines are available to stimulate postsynaptic 
monoamine receptors. MA also increases the quantity of biogenic amine available for release 
by inhibiting monoamine oxidases (MAOs; greater selectivity for MAO A over MAO B), key 
enzymes of amine catabolism located in the outer mitochondrial membrane (Sulzer et al. 2005). 
There are other properties that contribute to the effects of MA, which are, however, still under 
discussion. Some of them are the effect of MA on DA synthesis by enhancing tyrosine 
hydroxylase activity or the increase of CART peptides („cocaine-and-amphetamine-regulated-
transcript“) after the MA administration, in the brain areas connected to the reward system 
(Kimmel et al. 2000). It should be noted that the interaction of DA with other NTs such as GLU 
and GABA plays an important role in modulating the magnitude of the DA response to drugs 
(Cornish and Kalivas 2001).  
  
3.1.1.2 THE EFFECT OF METAMPHETAMINE 
In humans, with the low to moderate doses used in clinical experiments, the main MA 
responses include a reduction in fatigue, euphoria, positive mood and arousal. Subjects also 
describe higher self-confidence, decreased fear, reduced appetite, and increased alertness. 
Because of its peripheral sympathomimetic effect, even a small amount of MA can result in 
many physical effects, which include a rapid heart rate, irregular heartbeat, elevated blood 
pressure, increased respiration, increased body temperature and pupil dilatation. Cardiovascular 
and subjective effects appear to increase depending on the dose (Cruickshank and Dyer 2009). 
A high-dose of MA administrated intravenously (55-640 mg) evoked psychotic symptoms, 
aggressive behaviour, confused speech and motor restlessness. Long-term use of MA was 
shown to be connected with anxiety, confusion, insomnia and mood disturbances. Symptoms 
of psychosis, such as hallucinations, paranoia and delusions (for example, the sensation of 
insects crawling under the skin) were also reported among chronic users (Nordahl et al. 2003). 




increased risk of developing Parkinson's disease (Garwood et al. 2006). MA overdose is often 
recognised by tachycardia, hypertension, chest pain, shivering and an altered mental status 
including suicidal intensions and acute psychosis (Nordahl et al. 2003). In terms of MA 
withdrawal the most prominent symptoms are disturbed sleep, depressed mood, anxiety, 
craving, cognitive and concentration impairment, and anhedonia (McGregor et al. 2005). The 
MA withdrawal effects are thought to be originated from the depletion of presynaptic 
monoamine stores and down-regulation of the receptors and neurotoxicity (Barr et al. 2006).  
It has been demonstrated in animal studies that the physical effects of MA 
administration (a low dose ≤5 mg/kg) are similar to those found in humans. Those which can 
be seen the most are higher locomotion and vertical activity (Schutová et al. 2010, Šlamberová 
et al. 2011c). Stereotypical behaviour including repetitive motion, cage sniffing and licking, 
and nail biting have been also reported (Frohmader et al. 2010). It has been found that an 
increased DA neurotransmission in the NAc is responsible for the induced locomotion, while 
the stereotypical behaviour relies on an increase of DA in SN (Kelly et al. 1975). 
Studies indicate that repeated MA exposure leads to a long-lasting depletion of striatal 
DA and 5-HT, as well as damage to the striatal DA and 5-HT nerve terminals. The mechanisms 
of neurotoxicity are not yet fully understood. The initial study was done on rhesus monkeys, 
which received MA in low doses eight times a day for a period of four to six months (total of 
52 mg/kg of MA a day). After another period of six months without the drug they were 
sacrificed and a regional brain assay of transmitter levels was conducted. It was observed that 
MA-treated monkeys had significantly reduced regional DA levels (Fischman and Schuster 
1974, Seiden et al. 1976). In two other different species- rats and Guinea pigs, the repeated 
administration of MA was shown to cause long-lasting depletions of central DA (Wagner et al. 
1979). Experiments on primates also demonstrated that the MA induced neurotoxicity may 
require more than a year for complete recovery (Harvey et al. 2000). Since the first experiments, 
several hypotheses regarding the mechanism of MA-neurotoxicity have been proposed. One 
explanation is the auto-oxidation of cytosolic DA and 5-HT to 6-hydroxydopamine (6-OHDA) 
and 5, 6-dihydroxytriptamine. 6-OHDA is extremely unstable and hydrogen peroxide is 
generated during auto-oxidation of DA (Kita et al. 2003). The formation of DA-related reactive 
oxygen species (ROS) such as superoxide and hydroxyl radicals appears to play an important 
role in MA-induced neurotoxicity. It has also been shown, that the administration of 
antioxidants, such as ascorbic acid or vitamin E, decreased MA-induced neurotoxicity (Wagner 
et al. 1986). Other factors, which are thought to contribute to the neurotoxic effect, are an 




the cortico-striathothalamo-cortical negative feedback loop (Carlsson and Carlsson 1990). 
Interestingly, it appears that despite the structural similarities of DAT, SERT and NET, NA 
transporters are less vulnerable to oxidative inactivation (Haughey et al. 1999). Similarly to 
experimental studies, clinical studies with the help of PET and magnetic resonance imaging 
data also show brain abnormalities which persist further than the period of MA consumption, 
including inflammation, reduced density of DA markers such as DAT, D2 receptors in 
prefrontal cortex and basal ganglia, and reduced of VMAT2 and SERT. Striatal abnormalities, 
which correlate with different psychotic symptoms, impaired psychomotor coordination and 
memory deficits, persisted for years after the period of MA administration, but recovered 
partially after 6-12 months of abstinence (Sekine et al. 2003).  
 
3.1.1.3 PRENATAL METHAMPETAMINE EXPOSURE 
MA is one of the most frequently abused drugs by female addicts, especially during 
pregnancy. It is mostly taken because it decreases appetite and food intake and therefore helps 
women to control their weight, while increasing energy (Marwick 2000). Since MA is a 
lipophilic drug it can easily cross the blood-brain barrier (one of the most resistant barriers of 
the body), the placental barrier is even more easily permeable. Thus, if pregnant women don’t 
quit taking MA during pregnancy, they expose not only themselves but also their foetuses to 
the danger of the drug, and it might lead to causing harm to the developing foetus (Greenhill 
2006, Nordahl et al. 2003). 
Clinical studies have revealed that exposure to MA during pregnancy induces birth 
defects such as heart defects or cleft lift, small head circumference, undescended testicles and 
also lowers the birth weight (Oro and Dixon 1987). Additionally, increased muscle tone, tremor, 
irregular sleep and impaired adaptability to stress have also been shown (Wouldes et al. 2014). 
Quantitative morphological analysis showed a reduction in the volume of subcortical structures 
of the brain (putamen, globus pallidus and hippocampus) in children with prenatal MA exposure 
(Thompson et al. 2004). Not only structural abnormalities, but also delays in child development 
have been reported. Volume decrease in the affected brain areas correlated with a worse 
performance of attention and verbal memory (Chang et al. 2004). It should be noted, that the 
developmental impairment of the children of drug-abusing women might be affected by other 
factors, e.g. combining alcohol or smoking at the same time as taking drugs, or less careful 
prenatal as well as postnatal care of their children (Sowell et al. 2010, Vavřínková et al. 2001). 
Because clinical trials are restricted to statistical comparisons, the scientific research in 




It has been proven that prenatal MA exposure has harmful effects on both mothers and their 
offspring. Acuff-Smith et al. (1996) showed that repeated administration of pregnant rats with 
MA resulted in a higher incidence of delivery failure and the mother's death. It also shortened 
the gestation period, decreased the number of pups in the litter, and lowered the weight gain 
during pregnancy (Martin 1975, Martin et al. 1976, Šlamberová et al. 2006). In addition to 
growth restriction structural eye defects, delayed motor development, and learning impairments 
are also consistent findings in animals exposed to prenatal MA exposure (Acuff-Smith et al. 
1996). Prenatal MA exposure has been shown to affect development of postural movements of 
the pups in the first three week of postnatal life, which was shown in different tests (righting 
reflex in mid-air, righting reflex on surface, rotarod test and bar-holding test) (Šlamberová et 
al. 2006, Šlamberová et al. 2007). Also the time of the drug administration has been 
demonstrated to be crucial in the final effects of the drug. It has been shown that MA exposure 
during the first half of gestation hinders the early locomotion, while exposure during the second 
half of gestation leads to reduction in sensorimotor development (Acuff-Smith et al. 1996). 
There is a growing number of studies which show that changes in the brain caused by 
prenatal and neonatal MA exposure might persist into adulthood. Problems in adapting to a new 
environment, long-term cognitive deficits, as well as changes in locomotor activity have been 
previously shown (Acuff-Smith et al. 1996, Schutová et al. 2013, Šlamberová et al. 2005, 
Šlamberová et al. 2011c, Weissman and Caldecott-Hazard 1993, Williams et al. 2003). On the 
other hand, there are studies showing that exposure to MA in utero does not induce such 
changes, which would persist until adulthood as a reflexion of disturbance in various forms of 
behaviour (Schutová et al. 2008, Schutová et al. 2009)   
   
3.1.2 METHAMPHETAMINE VS. AMPHETAMINE 
MA and AMP are structurally similar drugs that are reported to share several 
pharmacokinetic and pharmacodynamic properties. Both belong to phenylethylamines, while 
MA is the N-methylated analogue of AMP (Melega et al. 1995). There is no consensus in 
literature as to which analogue is more potent. The commonly accepted opinion is that MA is 
more addictive and preferred by drug addicts than AMP and, despite structural similarities, MA 
has been suggested to be a more potent central stimulant with less peripheral activity (Peachey 
et al. 1977). However, disagreements over the effect of these two drugs at the key 
neurotransmitter pathways have been shown. Using in vivo microanalysis (Shoblock et al. 




administration on DA levels in the NAc. On the other hand, in the same study, AMP was shown 
to be more effective at rising DA levels in the PFC than MA, and also AMP raised GLU levels 
in the NAc while MA didn’t. Based on these findings, Shoblock et al. (2003b) suggested that 
AMP and its effect on the GLU release in the NAc might have a modulatory role in locomotor-
stimulating effect of this drug. Additionally, this increase in GLU and DA levels after AMP 
may activate other pathways that inhibit reward and thus cause a lower reinforcing effect of the 
drug. On the other hand, some other authors didn’t show any differences in the potencies of 
AMP and MA in either inducing locomotor activity (Milesi-Halle et al. 2007) or inducing 
release of DA (Melega et al. 1995). Moreover, MA was shown to have a three-fold greater 
potency than AMP in releasing 5-HT (Kuczenski et al. 1995). Because of the fact, that the PFC 
is connected to the performance of a working memory, a higher impact of AMP on this structure 
might be, according to Shoblock et al. (2003b), capable for causing deficits in working memory.  
 
3.1.3 3, 4-METHYLENEDIOXYMETHAMPHETAMINE  
N-methyl-3,4 -methylenedioxyamphetamine (MDMA) is a ‘club’ drug widely popular 
among young people in social situations thanks to its unique psychoactive effects, including 
mood elevation, evocation of feelings of empathy to others, mild hallucinations, increase of 
readiness and change of sensory perception (Parrott and Lasky 1998). 
 
3.1.3.1 PHARMACOKINETICS AND PHARMACODYNAMICS OF MDMA 
MDMA is usually taken orally, as a capsule or tablet and commonly in a combination 
with other drugs (cocaine, MA, ketamine). The drug's effect lasts approximately 3 to 6 hours, 
although it is common for users to take a second dose of the drug as the effects of the first dose 
begin to decline (Váchová et al. 1999). MDMA taken by humans is a mixture of (+) an (-) 
stereoisomers, and (+) MDMA is a stronger monoamine releaser than (-) MDMA (Baumann et 
al. 2007). Similarly to MA, MDMA interacts with monoamine transporters to reverse the 
normal direction of transmitter flux and thus cause a non-exocytotic release of three NTs (5-
HT, DA and NA) (Johnson et al. 1986, Spanos and Yamamoto 1989). MDMA exhibits 
somehow a greater affinity to SERT versus DA transporters and recent in vitro experiments 
suggested that MDMA is a stronger 5-HT releaser than DA in the nervous system (Verrico et 




3.1.3.2 THE EFFECT OF MDMA 
Acute 5-HT release after MDMA contributes to the unique subjective effects described 
by humans, which have been mentioned before (especially euphoria with mild hallucinations 
and feelings of closeness to others). Of the physical effects, irregular heartbeat, dehydration, 
hyperthermia and reduced appetite have been documented (Liechti and Vollenweider 2001). 
Additionally, some negative consequences for heavy MDMA users have been experienced, 
including confusion, depression, sleep problems, drug craving, reductions in social interactions, 
anxiety and problems with attention and memory (Bull et al. 2004, Morley et al. 2001, Parrott 
and Lasky 1998). Although, similarly to MA, MDMA-induced long-lasting reductions in basal 
levels of 5-HT, substantial loss of 5-HT reuptake transporters and an irreversible degeneration 
of 5-HT nerve terminals in rats (Baumann et al. 2007) and in humans (McCann et al. 2000, 
Quinton and Yamamoto 2006) have been reported, it is still unclear if MDMA-induced 
neurotoxic effects contribute to long-lasting changes.  
In experimental studies, MDMA causes different pattern of locomotion as those seen 
after MA administration. Typically, forward locomotion is presented by thigmotaxis and 
reduction in vertical activity, and stereotypic movements are presented by head weaving and 
forepaw treading (Hiramatsu et al. 1989, Spanos and Yamamoto 1989). It should be noted that 
forward locomotion relies on both, a release of DA and 5-HT. The NAc and striatal DA release 
after a microinjection of MDMA was shown to be connected to forward locomotion, and this 
process required both, D1 and D2 receptors (Bubar et al. 2004). Additionally, pre-treatment 
with selective 5-HT reuptake inhibitors attenuated an MDMA-induced 5-HT release as well as 
forward locomotion, and through the effect on 5-HT1B and 5-HT2A receptors MDMA facilitates 
this effect (Callaway et al. 1990, Gudelsky and Nash 1996). MDMA-induced stereotypic 
behaviour was shown to rely on a DA release in the striatum and a 5-HT release in the NAc, 
PFC and striatum (Baumann et al. 2008). The increased social interaction after acute MDMA 
treatment was shown to be linked to 5-HT1A receptors, which play a role in the control of the 
neurohormone oxytocin release (Morley and McGregor 2000). 
 
3.2 COCAINE 
Cocaine (COC) is a powerfully addictive psychostimulant drug, which causes a 
euphoric effect like that of MA and MDMA. However, it differs from these drugs in the 




mountains of Latin America. It has been chewed by members of Indian tribes for more than 
5000 years, and firstly isolated and introduced to other countries in 1859 (Dixon 1989).  
 
3.2.1 PHARMACOKINETICS AND PHARMACODYNAMICS OF COCAINE 
There are more ways by which COC can be used. The most popular ones are intranasal 
and intravenous. It can also be made into hydrolysed crystal “crack”, which can be smoked. 
The intensity and duration of COC's high effects depend on the way it is administrated. Injecting 
or smoking COC delivers the drug rapidly into the bloodstream producing a quick, strong and 
brief effect, while the ‘high’ from snorting might last 15 to 30 minutes (Dixon 1989). The 
plasma half-life of the drug is about 30-40 minutes and it is metabolised to benzoylecgonine 
and ecgonine and a positive result of using the drug can be identified by immunoassay of the 
urine five days after use. It was firstly shown in 1960 by Whitby et al. (1960) that COC blocks 
re-uptake of catecholamine, which is now acknowledged to be its primary mean of increasing 
extracellular levels. COC binds with comparable affinity to NETs, DATs and SERTs and the 
addictive qualities appear to be dependent on the blockade of DAT function (Rothman and 
Baumann 2003). 
 
3.2.2 THE EFFECT OF COCAINE  
The powerful euphoric effect of COC depends largely on DA release and it is 
represented by increased self-esteem and vigour, decreased fatigue and appetite and increased 
sexual prowess (Dixon 1989). The mostly described physical effects after cocaine use are: an 
increase in body temperature, heat rate and blood pressure and sometimes nausea. Some 
additional adverse effects of the drug have been described after chronic COC use, including 
psychosis, insomnia, depression, mood disturbances, loss of appetite and aggressive behaviour 
(Williamson et al. 1997). Because of its powerful vasoconstrictive effect, the drug is often 
connected to sudden death caused by heart attacks and strokes (Dixon 1989). It has been stated 
that chronic use of COC has a neurotoxic effect on the dopaminergic system and this hypothesis 
has been shown by clinical findings showing a lasting decrease in DA in the brains of COC 
addicts (Dackis and Gold 1985, Wilson et al. 1992).  
In animal models COC administration was shown to be connected to psychomotor 
sensitisation, which relies on excitatory neurotransmission in the VTA (Ungless et al. 2001). 
Ungless et al. (2001) demonstrated a long-lasting synaptic potentiation in VTA after a single 




in a COC-induced self-administration (Caine and Koob 1994, Thomas et al. 2008). The 
reinforcing effect of COC has been demonstrated by attenuation of COC self-administration 
after a selective lesion of DA terminals with 6-hydroxy DA (Caine and Koob 1994). 
 
3.3 OTHER DRUGS OF ABUSE 
3.3.1 OPIOIDS 
The term ‘opiates’ describes all agents which are originally derived from opium 
(extracted from the opium poppy Papaver somniferum L). While opioids are defined as all 
drugs, natural and synthetic, with a morphine-like action, such as diacetylmorphine- heroin, 
codeine and dihydrocodeine, oxycodone, hydrocodone and buprenorphine. Some other 
synthetic opioids are methadone, fentanyl, naloxone, levorfanol and many others (Bečková and 
Višňovský1999b). They have a major medical use in the treatment of diarrhoea and pain. Out 
of these MOR has been used for pain relief for a long period of time. However, their beneficial 
medical effects are accompanied by significant side effects, the most devastating being opioid 
addiction which comes with chronic uncontrolled use (Koob and Moal 2006b).  
 
3.3.1.1 PHARMACOKINETICS AND PHARMACODYNAMICS OF MORPHINE 
Morphine (MOR) was first isolated from opium in 1804, and it was named after 
Morpheus, the God of Dreams, or Morphina, the God of Sleep (Koob and Moal 2006b). It is 
one of the most powerful and effective drugs for pain relief (Bečková and Višňovský1999b, 
Koob and Moal 2006b). However, its use within or outside of medical situations leads to an 
intractable physiological dependence and addiction. Intramuscular and subcutaneous 
administrations are the most common routes of administration with MOR-addicted people. 
Additionally, MOR injected intravenously is a sign of a strong MOR-addiction (Bečková and 
Višňovský1999b, Martin 1983). The liver is probably the major site of MOR metabolism with 
morphine 6-β-glucuronide and 3-β-glucuronide being the most dominant metabolites. 3-β-
glucuronide has no analgesic activity and it is thought to be rather toxic, having also some 
excitatory effects. By contrast 6-β-glucuronide is believed to have similar analgesic qualities 
compared with MOR (Osborne et al. 1988, Penson et al. 2000). The plasma concentration 
differs based on the type of application, with peak plasma levels 20 minutes after intramuscular 
injection ranging from 51 to 62 ng/ml (Stanski et al. 1978). 
MOR interacts predominantly with the opioid mu (μ)-receptor. These μ -binding sites 




within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the 
trigeminal nerve. They also show a high concentration in the posterior amygdala, 
hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas (Koob and Moal 
2006b). As discussed later, it is still not fully understood which structures play a preliminary 
role in the neurobiology of the acute reinforcing effect of opioids. 
 
3.3.1.2 THE EFFECT OF MORPHINE 
Intoxication with MOR following an intravenous injection has been described as having 
four different phases. Firstly, there is a profound euphoria (sometimes termed as a rush) 
including visceral sensations. Secondly, euphoria is then followed by a feeling of well-being 
which can extend for several hours. Thirdly, a state of nods is described as an escape from 
reality to virtual unconsciousness. In the last phase the user is no longer experiencing the rush 
but not yet experiencing withdrawal. This state can last for up to 8 hours usually followed by 
another injection of the drug. However, how long the final effect lasts for depends on, if the 
drug user takes the drug chronically or if it is their first contact with the drug (Dole 1980). An 
overdose might be connected to an increased risk of depressed respiration leading to coma and 
death. The symptoms of MOR withdrawal were well described by and include elevation in 
temperature and blood pressure, perspiration, yawning, diarrhoea, goose bumps, muscle 
spasms, restlessness and insomnia. Anxiety and depressive-like symptoms have also been 
described (Bečková and Višňovský 1999b). 
In animal models MOR administration increased locomotor activity in a dose dependent 
manner (Babbini and Davis 1972, Vezina et al. 1987). Accordingly to Nader and van der Kooy 
(1997) two separate motivational systems are involved in the reinforcing effect of opioids. The 
Mesocorticolimbic DA system is only important in mediating the motivational effects when an 
animal is in a deprived state (i.e., opiate-dependent) and the pedunculopontine tegmental 
nucleus of the brain stem mediates MOR's rewarding properties only when an animal is in a 
nondeprived state (not in a state of withdrawal - previously drug-naive rats). The self-
administration of intravenously delivered MOR was first shown in 1960' by Weeks (1962) and 
by Thompson and Schuster (1964) in the Rhesus monkey, and since then studies have shown 
the lateral hypothalamus, the NAc, the amygdala and the VTA to be involved in MOR self-
administration (Bozarth and Wise 1981). There are more ways how MOR administration affects 
DA neurotransmission. Firstly, MOR increases DA release through activity on μ receptors on 




turn disinhibiting DA neurons (Johnson and North 1992). In addition, MOR increases burst 
firing of DA neurons in VTA (Nowycky et al. 1978).  
 
3.3.2 CANNABINOIDS  
Originally, the term cannabinoids referred to the phytocannabinoids of a plant Cannabis 
sativa L., but today the term includes all ligands of cannabinoid receptors and related 
compounds, comprising of endogenous ligands and a large number of synthetic cannabinoids 
ligands (Grotenhermen 2004). To present, 66 phytocannabinoids have been identified: 
cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), delta9-
tetrahydrocannabinol (THC), delta8-THC and other types (Elsohly and Slade 2005). The most 
important cannabinoids present in the plant are delta9-THC, CBD, CBG and CBC, however 
delta9-THC is thought to be the primary active one in the resins of the marijuana plant. Some 
of the other ones produce similar behavioural and physiological effects of THC, some others 
only alter the effect of THC and contribute to its subjective outcome (Wachtel et al. 2002). 
 
3.3.2.1 PHARMACOKINETICS AND PHARMACODYNAMICS OF DELTA9-
TETRAHYDROCANNABINOL  
Cannabis products are commonly either inhaled by smoking a cigarette, or taken orally 
as capsules or in cooked foods and liquids. Some other routes of administration include 
intravenous, eye drops or aerosols and inhalation with vaporisers (Grotenhermen 2004). The 
plasma concentration differs based on the type of application, with a peak 3-10 minutes after 
the onset of smoking, 20-30 minutes after intravenous administration, and 60-120 minutes with 
oral use. Metabolism of THC mainly takes place in the liver by microsomal hydroxylation and 
oxidation, and at least 100 metabolites have been identified, out of which 11-OH-THC is one 
with a similar action to its parent molecule (Harvey and Brown 1991). One single dose of THC 
might be detectable in the urine for usually 3-5 days, and sometimes up to 12 days (Schwartz 
et al. 1985). 
The delta9-THC receptors have been identified and cloned in 1990 as the cannabinoid 
CB receptors (Matsuda et al. 1990). Subsequently after the identification of the CB1 receptor 
the CB2 receptor was discovered, but only the CB1 receptors are normally found in the brain, 
the spinal cord and the peripheral nervous system (Pertwee 1997). Activation of CB1 receptors 
produces a marijuana-like effect on behaviour and circulation, while activation of CB2 




receptors, however its effectiveness is less at CB2 than at CB1 (Grotenhermen 2004). Several 
endocannabinoids, which naturally bind to CB1 receptors, have recently been discovered, from 
which the well-known ones are anandamide and 2-arachidonylglycerol (Mechoulam et al. 
1998). 
 
3.3.2.2 THE EFFECT OF THC  
Numerous effects have been reported after THC use. The effect is characterised by a 
unique psychological mixture of depressant and stimulant effects, which can be divided into 
four groups: affective (euphoria, enhanced well-being, anxiety), sensory (increased perception 
of external stimuli), somatic (feeling of the body floating) and cognitive (disturbed memory, 
difficulty in concentration). Apart from the effect on the central nervous system, the circulatory 
system is also affected. Tachycardia, vasodilatation and enhanced heart activity are commonly 
seen, sometimes leading to fatal consequences (Grotenhermen 2004). It is still under discussion 
whether heavy regular use may impair cognition, however, a disruption of sensory processing 
and impaired learning and memory have already been reported in humans after THC 
administration (D'Souza et al. 2004, Ramaekers et al. 2006). A cessation of long-term 
administration of THC has been shown to lead to withdrawal effects including insomnia, 
sweating and inner unrest, though symptoms are mild and a risk of physical and psychic 
dependence is low when compared to other drugs of abuse (Grotenhermen 2004). 
As with other drugs of abuse, THC is believed to induce a rewarding effect on the central 
VTA-NAc circuit, however, the specific mechanism of the DA release after cannabinoids has 
not yet been identified (Lupica et al. 2004). It has been demonstrated using the CB1 receptor 
agonist that the increase of DA release in VTA might be caused by a local disinhibitory 
mechanism, in which inhibition of a GABA release via activation of the CB1 receptors leads to 
a higher activity of DA neurons (Szabo et al. 2002). Rewarding properties similar to those found 
after other drugs of abuse have been supported using preclinical studies. Braida et al. (2004) 
showed a reinforcing effect of a low THC administration in a self-administration test as well as 
in the conditioned place preference test. THC has also been shown to have an antinociceptive, 
hypothermic and motor activity-decreasing effect on laboratory mice and rats (Schramm-





3.4 GENDER DIFFERENCES IN DRUG ABUSE 
Traditionally, drug abuse is considered to be primarily a problem specific to men (World 
Drug Report 2015). However, numerous sex differences found in recent years have brought 
attention to drug abuse in women, and thus the need to consider drug abuse from different 
biological basis. Although the role of sex in the mechanisms of drug action remains unclear, 
clinical, as well as preclinical studies, indicates that ovarian hormones, oestrogen specifically, 
play a key role in producing sex differences in drug abuse (Lynch et al. 2002). The following 
chapters are focused on preclinical and clinical findings of sex differences and possible 
mechanisms that might underline these differences.  
 
3.4.1 PRECLINICAL STUDIES  
Several preclinical studies demonstrated that female rodents are more vulnerable than 
male rodents following treatment with AMP (Bisagno et al. 2003, White et al. 2002), cocaine 
(Cailhol and Mormede 1999, Lynch and Carroll 1999), MA (Roth and Carroll 2004, Schindler 
et al. 2002), MDMA (Páleníček et al. 2005), cannabinoids (Tseng and Craft 2001) and heroin 
(Lynch and Carroll 1999, Roth et al. 2002). In particular, locomotor activity and stereotypical 
behaviour were shown to be higher in female rats compared to males following acute and 
chronic AMP treatment (Bisagno et al. 2003) and acute and chronic MA treatment (Schindler 
et al. 2002, Schutová et al. 2013). Females were also reported to have an increased motivation 
for self-administration of cocaine and MA (Kučerová et al. 2009, Lynch and Carroll 1999). 
Additionally, female rats showed more problems with spatial memory after an acute dose of 
AMP (Bisagno et al. 2003). The most current opinion is that sex-related differences in the 
behavioural effect of drugs are based on sexual dimorphism in the NT system. A higher density 
in D1 receptors in the NAc was shown in female rats when compared to male rats (Andersen 
and Teicher 2000). Moreover, Walker et al. (2000) using a fast-scan cyclic voltammetry in 
anesthetized rats provided evidence that DA release and an uptake in the striatum is greater in 
female rats than in male rats. Variations in levels of cytochrome P-450 and other enzymes are 
also thought to play a critical role in different drug eliminations in females and males (Kato and 
Yamazoe 1992). Recently, higher concentrations of MA were revealed in a female rat's brain 
and plasma compared to a male's, following a single dose of MA (Rambousek et al. 2014). 
It has been reported that females show a greater response to drugs in the oestrus when 
compared to other phases of the oestrous cycle (Becker 1990). It is well known, that during the 




behavioural responses to psychostimulants. Figure 2 shows the oestrous cycle of a female rat 
divided into four phases: 1) proestrus (oestradiol rises to the highest level and progesterone 
level is low at the beginning and rapidly rises and decreases at the end), 2) oestrus (oestradiol 
and progesterone levels rapidly decline), 3) metestrus (oestradiol level is low and progesterone 




Figure 2: Changes in levels of oestrogen and progesterone throughout the phases of the rat 
oestrous cycle. The shaded bars separate the successive oestrous cycle phase 1) D- diestrus, 2) 
P- proestrus, 3) E- oestrus, 4) M- metestrus to identify the start and end of each phase. Prog- 
progesterone, E2- oestradiol. From: Lynch et al. (2002). 
 
Oestrogen appears to have a dominant role in the enhanced responsiveness to 
psychostimulants in female rodents. This statement has been supported by studies using 
ovariectomized (OVX) females treated with oestrogen. Oestrogen treatment in OVX females 
has been shown to enhance behavioural responsiveness to COC (Sell et al. 2000) and AMP 
(Becker 1990) when compared to OVX females with no hormone treatment. Moreover, acute 
administration of oestrogen to OVX females was shown to induce a rapid increase in AMP-
induced striatal DA release (Becker and Cha 1989, Becker 1990). Less is known about the 
mechanisms through which oestrogen acts in the striatum to enhance DA release in female rats. 
Two hypotheses have been stated by Becker (1999). Firstly, oestrogen acts on intrinsic medium 
spiny striatal neurons, which are primarily GABA neurons. This effect results in a decreased 
firing of recurrent collaterals that synapse on GABA receptors found on DA terminals. This, in 




Secondly, oestrogen acts directly on DA terminals and downregulate the D2 DA autoreceptors, 




Figure 3: Two mechanisms postulated to contribute to the effect of oestrogen (E) on 
stimulation of DA release. #1: Oestrogen acts to inhibit intrinsic GABA neurons that have 
recurrent collaterals onto DA terminals. This results in a greater DA release.  # 2: Oestrogen 
acts on DA terminals to enhance DA release by downregulating presynaptic D2 DA receptors. 
From: Becker (1999). 
 
3.4.2 CLINICAL STUDIES  
It should be noted that based on the epidemiological data from the American National 
Survey on Drug Use and Health (2014), adult men are more likely, compared to adult women, 
to be illicit substance users (11.5 % to 7.3%). Additionally, it has been shown that men are 2-3 
times more likely to develop some type of drug dependence disorder than women (Brady and 
Randall 1999). It has also been shown that men differ in their biological response to drugs when 
compared to women. Results from a study investigating the effects of intranasal COC use 
indicate that women report weaker subjective effects compared to men (Lukas et al. 1996). As 
far as the pattern of use is concerned (Hser et al. 1987) reported no differences between the 
sexes in the time spent using the illicit drug, amount of substance abused or abstinence periods. 
Moreover, for women it takes a shorter period of time to progress from recreational user to drug 
addict (Hser et al. 1987, Westermeyer and Boedicker 2000). On the other hand, it is not clear 




sides, however, females were shown more likely to attribute relapse to a stressful event (Lynch 
et al. 2002). 
Gender differences in four major determinants of pharmacokinetic variability have been 
revealed - bioavailability, distribution, metabolism and elimination. Changes in bioavailability 
depend on the route of drug administration and differences in the organs of absorption. 
Especially in the case of drugs with an oral route administration, gastrointestinal motility which 
has been shown to be affected by sex hormones plays a significant part in a drug's 
bioavailability. The distribution of a drug is influenced by numerous factors including mass 
index, body composition and plasma levels as well. As far as metabolism is concerned, the 
leading role in determining gender differences is thought to be played by the CYP450 
superfamily (Franconi et al. 2007).  
Similarly to preclinical studies, sex differences in the striatal DA system have been 
observed in humans (Kaasinen et al. 2001, Munro et al. 2006). For example, women have been 
reported to exhibit higher concentration of D2 receptors than men in the frontal cortex 
(Kaasinen et al. 2001). Additionally, a higher concentration of DA transporters in the striatum 
has been shown in women compared to men (Mozley et al. 2001). Interestingly, the reverse 
effect following a single administration of AMP on DA release in healthy adult women and 
men was reported in a study by Munro et al. (2006). They showed using PET studies greater 
DA release in the ventral striatum, the anterior putamen, and anterior and posterior caudate 
nuclei of men compared to women. Additionally, greater DA release in men was associated 
with greater subjective responses to AMP and COC in men compared to women (Oswald et al. 
2005). As with animals, in humans, the ovarian hormones are also important in the way the 
different genders respond drugs of abuse. Three main phases of the menstrual cycle are 
presented: 1) the follicular (the oestrogen level is low at the beginning and moderate later, the 
progesterone level is low), 2) the peri-ovulatory (the oestrogen level peaks and declines, 
progesterone level begins to increase) and 3) the luteal (the oestrogen level is moderate and 
progesterone level is high (Lynch et al. 2002). Positive correlation between increased plasma 
level of oestrogen and increased positive subjective effects were found in females as a response 
to AMP and COC treatment in the follicular phase compared to the luteal phase (Justice and De 
Wit 2000, Sofuoglu et al. 1999).  
   
4 THE SENSITISATION  
In the context of the study of drug addiction, two important terms are defined. The first 




administration, when the drug is being exposed continuously. On the other hand, behavioural 
or psychomotor sensitisation (BS) is defined as a progressive and enduring response produced 
by repeated intermittent drug administration with the same or lower dose (Suzuki et al. 2004). 
Other terms that refer to the BS are reverse tolerance, behavioural augmentation or facilitation 
(Robinson and Becker 1986). The phenomenon of BS to the effects of various drugs has been 
observed in several preclinical studies [for COC (Estelles et al. 2006), MA (Schutová et al. 
2009, Schutová et al. 2010, Šlamberová et al. 2011b, Šlamberová et al. 2011c), and MOR 
(Valjent et al. 2010)] and others. It should be noted that the interval between drug applications 
is an essential variable. The closer together in time injections are, the greater likelihood that 
tolerance will develop, and the sensitisation is less likely (Post 1980). It was found that this 
enhanced drug sensitivity persists for very long periods of time. Even though only one single 
injection might be sufficient for its development, repeated administration produces more 
enhanced effect (Robinson and Becker 1986). For example, Magos (1969) reported that in rats 
two injections of AMP (6 mg/kg), given 2-5 weeks apart, enhanced the behavioural response 
produced by the third injection given 4 weeks later.  
Robinson and Berridge (1993) claim that with a repeated intermittent drug 
administration, brain regions involved in a reward system become hypersensitive to a specific 
drug effect, which results in a pathological drug craving. Despite numerous studies 
investigating sensitisation as a complex process arising from different cellular changes in many 
brain regions, the neural basis of behavioural sensitisation has not been thoroughly 
characterized. To answer the question ‘what is the locus of the neural changes underlie 
behavioural sensitisation ’, different hypothesis have been proposed. According to the neural 
hypothesis, two phases of BS can be defined. The initiation of BS occurs in the VTA and it is 
defined by a transient sequence of cellular and molecular changes caused by drug 
administration. While the neuronal events associated with expression of BS are distributed 
among the interconnected nuclei of the motivation circuit and are defined as enduring neural 
alterations from the initiation process (Kalivas and Stewart 1991, Robinson and Becker 1986). 
The development of BS after repeated intermittent psychostimulant administration is 
specifically based on changes in the DA system- nigrostriatal, mesolimbic and mesocortical 
systems (Robinson and Becker 1986). This is to be expected because psychostimulants cause 
striatal DA release, and much of the behaviour which is sensitised by them is thought to be 
caused by increased DA release (Fukakusa et al. 2008, Sulzer et al. 2005, Vanderschuren and 
Kalivas 2000). While the increase in extracellular DA at terminals (NAc) following repeated 




extracellular DA level in VTA is sufficient for the induction of BS (Kalivas and Stewart 1991). 
Similar to animal models, repeated intermittent administration of AMP was reported to cause 
sensitisation  of DA release in humans, even when an one dose of  acute drug is given a year 
later (Boileau et al. 2006). Figure 4 schematically illustrates some of the changes in brain DA 
neurons that occur following repeated intermittent AMP administration. Apart from enhanced 
DA release, some other cellular changes are suggested to accompany BS (Robinson and Becker 
1986). Although the essential role of D1 receptors in the induction of BS has been declared in 
previously published studies using D1 receptors antagonists, the involvement of D2 receptors 
in this process is still less clear (Ujike et al. 1989, Vezina and Stewart 1989). Additionally, not 
only DA but also other neurotransmitters (NTs) have been shown to be needed for BS induction 
after psychostimulants treatment (Kalivas and Alesdatter 1993, Wolf 1998). Specifically, 
increased GLU transmission in the NAc, striatum and VTA was reported after repeated 
intracranial AMP administration (Wolf 1998, Xue et al. 1996). Moreover, using pre-treatment 
with non-competitive NMDA antagonist, MK-801, the induction of BS was inhibited, 
indicating the NMDA and AMPA receptors to be involved (Stewart and Druhan 1993, Wolf 
and Jeziorski 1993). 
 
Figure 4: A: An illustration of DA release from dopamine terminals after the first time of AMP 
administration. B: An illustration of DA release from dopamine terminals after the animal has 
been sensitised to AMP (1- enhanced DA release, 2- changes in postsynaptic DA receptors, 3- 
DA autoreceptors sensitivity, 4- presynaptic facilitation by hyperpolarization of the DA 
terminals via a presynaptic input, 5- a shift in the distribution of DA from a storage pool. Black 
dots represent DA. Postsynaptic DA receptors are black, presynaptic DA autoreceptors are 
white, and presynaptic receptor receiving a hyperpolarizing input from another cell is striped. 




There are an increasing number of studies which show that abuse of one drug leads to 
an increased sensitivity to another drug. This effect of a developed general drug sensitivity is 
called cross-sensitisation (Shuster et al. 1977) and has been reported between drugs of similar 
mechanisms of action like AMP and cocaine (Horger et al. 1992, Shuster et al. 1977) or between 
methylphenidate and AMP (Valvassori et al. 2007). Repeated AMP pre-treatment was first 
shown to sensitised animals to the locomotor activating effect of COC (Shuster et al. 1977). In 
another study, pre-treatment with AMP enhanced the acquisition of COC self-administration 
(Ferrario and Robinson 2007). Moreover, cross-sensitisation has also been demonstrated 
between drugs with different mechanisms of action, e.g. between opioids and COC (He and 
Grasing 2004, Leri et al. 2003) and between endocannabinoids and opioids (Fattore et al. 2005, 
Vela et al. 1998),  
Furthermore there are studies which show that the exposure to a drug of abuse in utero 
causes such differences in the brain of a developing animal, which results in a development of 
a higher predisposition to drugs of abuse in adulthood (Malanga and Kosofsky 2003). Increased 
tendency of drug abuse in adulthood has been shown in prenatally MA-exposed (Schutová et 
al. 2010, Šlamberová et al. 2011c), COC-exposed (Keller et al. 1996, Rocha et al. 2002) 
cannabinoid-exposed (Vela et al. 1998) and MOR-exposed (Gagin et al. 1997) offspring 
compared to controls. In a study by Bubeníková-Valešová et al. (2009) offspring with prenatal 
MA exposure had increased brain levels of DA after a challenge dose of MA in adulthood, 
which suggests increased sensitivity to MA after prenatal treatment. The effect of the drug 
administrated prenatally has been documented to be dose dependent. A low dose of MA (2 
mg/kg) decreased the expression of DA transporters in the striatum and 5-HT transporters in 
the hippocampus, striatum and hypothalamus. On the other hand, a high dose (10 mg/kg) 
increased the concentration of binding sides for the uptake of DA and 5-HT suggesting a 
stimulating growth effect of the particular axon terminals (Weissman and Caldecott-Hazard 
1993), while Heller et al. (2001) showed MA at a toxic dose of 40 mg/kg not affecting the basal 
level of DA, but to increase the DA level in the striatum and tegmentum after the challenge 
dose of MA. MA at a dose of 5-20 mg/kg is used in experimental studies because it leads to 
such drug concentrations in the brain that correspond to the amount in the foetuses of the drug-
dependent mothers (Acuff-Smith et al. 1996,Martin et al. 1976). Although there is still little 
known about how the MA exposure in utero interacts with the neurotransmitter systems of the 
developing brain and how this interaction affects the development of predisposition for 




4.1 TESTING OF SENSITISING DRUG'S EFFECT 
Traditionally, there are three test models used for testing behavioural or locomotor 
sensitisation (Malanga and Kosofsky 2003). Firstly, there is an intravenous self-administration, 
which measures drug-seeking behaviour, in which the reward depends on the animal's operant 
behaviour. In anthropomorphic terms, it represents how much the animal “likes” or “wants” the 
drug. Then, there are the Conditioned Place Preference test (the CPP test) and the test for 
examining spontaneous locomotor activity of an animal in an unknown environment (the 
Laboras test, Open field test). In these two tests the reward doesn’t depend on the animal's 
behaviour. Specifically, in the CPP test, an animal demonstrates preference for an environment 
which has been paired with a drug, and this is thought to be a model of cue-induced craving 
seen in human addicts. Last but not least, the Laboras test is conducted to test augmented 
locomotor activity produced by repeated drug administration, in anthropomorphic terms, drug-
induced euphoria (Malanga and Kosofsky 2003). The general pattern of induction of locomotor 
stimulation in a psychostimulant addict and in an animal model is illustrated in Fig. 5. The 
augmented motor activity is observed after readministration the drug following discontinuation 
of the repeated injection regimen (Pierce and Kalivas 1997). Different types of animal 
behaviour have previously been reported as a response to repeated intermittent 
psychostimulants administration (e.g. more intense stereotyped behaviour including repetitive 
head movement, increased forward locomotion, rotational behaviour, acoustic startle 
behaviour, cage climbing and others) (Malanga and Kosofsky 2003). It was discovered that the 
expression of BS is strengthened by the association of drug injection with environmental cues. 
BS was not manifested if animals were tested in a context where drugs have never been 
experienced (Anagnostaras and Robinson 1996, Duvauchelle et al. 2000).   
There are fewer studies researching the behavioural expression of sensitisation  in 
humans, however, eye-blink responses, increased vigour and energy ratings was shown to be 
caused by repeated administration of amphetamines in humans (Strakowski and Sax 1998). 
Also, drug readministration were shown to be followed by paranoia and psychosis (Pierce and 






Figure 5: Induction of psychostimulant-induced sensitisation in animal and human 
models. From: Pierce and Kalivas (1997). 
 
Previous studies have shown that prenatal MA exposure might sensitise the animals not 
only to the locomotor-stimulating effect of drugs administrated later in adulthood, but could be 
responsible for a modified reaction to the other drugs' effect. For example, (Schutová et al. 
2010) found that prenatal MA altered the responsiveness of adult male rats to acute MA 
administration. Specifically, they found that prenatally MA-exposed males demonstrated 
increased anxiolytic behaviour in the Elevated Plus Maze (EPM) test when compared to 
prenatally saline-exposed males. This result indicated that prenatal MA exposure might 
sensitise the animals to the anxiogenic behaviour of an acute MA treatment. In another study 
by Schutová et al. (2009) the effect of prenatal MA exposure on spatial learning in the Morris 
Water Maze test after chronic treatment with MA was examined. Contrary to the EPM study, 
this study revealed that prenatal MA exposure did not sensitise animals to the worsening effect 
of chronic MA on the parameters of spatial learning.  Moreover, in a study by Šlamberová et 
al. (2008) prenatal MA was shown to increase the sensitivity to a challenge dose of MA in a 
model of seizures induced by kainic acid.  
These are interesting findings which highlight the fact, that sensitisation doesn’t have to 
be only understood as a classical concept of augmented locomotor reaction after treatment with 
various drugs. These findings have lead us to extend the methodological part of various test 
models, which were used for examining different forms of behaviour as a reaction to acute or 








II. EXPERIMENTAL PART  
5 HYPOTHESIS AND AIMS 
Previous works, using drugs, have shown that prenatal MA exposure increases 
sensitivity to acute drug treatment in adulthood. Not only has sensitisation to the same drug 
been shown, but also “cross-sensitisation” between drugs with different mechanisms of action. 
Moreover, evidence shows that female rats tend to react differently to the effect of 




Regarding the above mentioned findings the following hypothesis were set up: 
Prenatal methamphetamine increases the sensitivity: 
A.  to the same drug treatment in adults (methamphetamine) 
B.  to drug treatment with drugs having a similar mechanism of action (amphetamine, 
cocaine, MDMA) 




1) To determine the sensitising effect of prenatal MA exposure using the following tests: 
a) for active drug seeking behaviour (the Conditioned Place Preference test), 
b) for locomotor behaviour  (the Laboras test). 
 
2) To determine if prenatal MA exposure increases sensitivity to any of the other known 
effects of the tested drugs, the following tests were used: 
a) for social behaviour (the Social Interaction test), 
b) for anxiety (the Elevated Plus Maze test), 
c) for spatial learning and memory (the Morris Water Maze test). 
 
3) To determine if sex differences affected drug treatment outcomes, tests were carried out 




6 MATERIALS AND METHODS  
All procedures were performed in accordance with the Ethical Guidelines of the Third 
Faculty of Medicine, Charles University in Prague, Czech Republic and reviewed and approved 
by the Institutional Animal Care and Use Committee and in agreement with the Czech 
Government Requirements under the Policy of Humans Care of Laboratory Animals (No. 
246/1992) with the subsequent regulations of the Ministry of Agriculture of the Czech Republic 
(as Project of the Experiment No. 79). 
 
6.1  ANIMALS AND PRENATAL DRUG ADMINISTRATION  
Adult female and male Wistar rats were delivered by Anlab (Prague, the Czech 
Republic) from Charles River Laboratories International, Inc. They were housed for 4 females 
- 5 males respectively per cage and left undisturbed for a week in a temperature-controlled 
colony room (22-24°C) with free access to food and water on 12 h (light):12 h (dark) cycle with 
lights on from 6:00. After the acclimatization period females were smeared with vaginal lavage 
to determine the phase of their oestrous cycle. When the oestrous phase was reached females 
were housed overnight with sexually mature males. There were always two female rats and one 
male rat per cage. The following morning females were smeared for the presence of sperms and 
returned to their home cages. The day when sperms were detected was designated as day 1 of 
gestation (GD 1). Animals were randomly assigned to two treatment groups through the entire 
gestation period: half of the females were injected subcutaneously (s. c.) with MA (5 mg/kg) 
and the other half with saline (1 ml/kg). The dose chosen was based on the previous studies 
(Šlamberová et al. 2005, Šlamberová et al. 2006). Females were injected daily throughout the 
entire gestation period (GD 1-22).  
The day of delivery was counted as postnatal day (PD) 0. On PD 1, pups were weighted 
and tattooed for father identification. Prenatally MA-exposed pups were injected intradermally 
with black India ink in the left foot and prenatally saline-exposed pups in the right foot. All 
litters were adjusted to twelve. To avoid litter bias pups were cross-fostered so that each mother 
had six prenatally MA-exposed pups (3 males and 3 females) and six prenatally saline-exposed 
pups (3 males and 3 females). On PD 21, the animals were weaned and separated according to 
sex. They were left undisturbed until adulthood, when they were tested in following behavioural 
tests. Always one prenatally saline-exposed and one prenatally MA-exposed female and male, 
respectively, per group and test were used from each litter to avoid litter effects. Animals were 




on from 6:00 (the Morris Water Maze test and the Elevated Plus Maze test) or on reversed cycle 
with lights on from 18:00 (the Conditioned Place Preference test, the Laboras test, and the 
Social Interaction test). 
 
6.2 BEHAVIOURAL TESTS 
6.2.1 THE CONDITIONED PLACE PREFERENCE TEST  
The Conditioned Place test (CPP) is a test used for examining an active drug-seeking 
behaviour of an animal. As mentioned before, the CPP test reflects a preference for an 
environment due to the contiguous association between the environment and a drug-associated 
stimulus based on the Pavlovian conditioning principles (Šlamberová et al. 2012).  
In our experiment, the Conditioned Place Preference apparatus was made of Plexiglas, 
with two main compartments [25x25x25 cm (l x w x h)] and one central (neutral) compartment 
(15x25x25 cm) (Fig. 6). The central compartment was detached from the main chambers by 
removable doors. Walls of one of the main chambers were painted with 2.5-cm-wide alternating 
black and white horizontal lines; walls of the other main chamber were painted with 2.5-cm-
wide alternating black and white vertical lines. The central compartment was made of a grey 
opaque Plexiglas. The central compartment had a smooth Plexiglas floor, while the floor of 
both main compartments was made of wire mesh with different size of the meshes. The CPP 
apparatus dimensions and a general procedure were modified accordingly to the work by 
Sanchez et al. (2003). 
 The CPP test was divided into three phases: pre-exposure, conditioning and the CPP 
test accordingly to Mueller and Stewart (2000) and Šlamberová et al. (2011b). Both, adult male 
and female rats were tested in the CPP test. 
1) The Pre-exposure: On the Day 1, animals received a single pre-exposure test in which they 
were placed in the centre compartment with the doors open, so they were allowed to access 
to the entire apparatus for 15 min. The total time spent in each chamber and the amount of 
entries was measured and used to assess unconditioned preferences.  
2) The Conditioning: The following conditioning phase lasted for 8 days. Each day during 
this phase rats were assigned to receive drug pairings with one of the two chambers in a 
counterbalanced fashion (the ‘unbiased’ procedure). Half of each group started the 
experiment on the drug-paired side and the other half on the saline-paired side. On alternate 
days, rats received either saline (1.0 ml/kg) or drug s. c. prior to being placed in the other 




explore the specific chamber for 1 hour. Half of each treatment group received drug 
injections on the 2nd, 4th, 6th and 8th day; the remaining subjects on the 3rd, 5th, 7th, 9th 
day. The central compartment was not used during this phase of the test and was blocked 
by the doors.  
3) The CPP test: On the Day 12, a test for the CPP was given. Animals were placed in the 
central compartment with the doors opened and thus allowed them a free access to the 
entire apparatus for 15 min. The time spent in each chamber and the number of entries was 
recorded to assess individual preferences. No injections were given during the CPP test, 
maintaining the same procedure as that used during the pre-exposure test. 
 
 
Figure 6: Animal in the Conditioned Place Preference apparatus. 
 
6.2.2 THE LABORAS TEST  
The Laboras test is a modified fully automated Open field test used for examining 
animal’s locomotor behaviour, exploratory behaviour and general activity in an unknown 
environment. The Laboras test is an advanced and completely non-invasive system that 
automatically recognizes several normal and special behaviours of rats by analysis of the forces 
that are induced by the activities of the animal (Animal behaviour research, 2015a). 
In our experiment, the Laboras apparatus was a triangular shaped cage (45 x 25 x 30cm) 
located in a dark room, and with walls made of Plexiglass (Fig. 7). It stood on a sensor platform 
connected to a computer. When the animal moved in the cage, platform recorded vibrations 
evoked by an animal’s movements. Each behaviour had its own unique signal signature which 




Rats were injected either with saline (1.0 ml/kg) or drug s. c. and placed in the centre of 
the Laboras cage (Tab. 3, 4, 5). There was no habituation to the apparatus before the testing, so 
it means that the rats were exposed to a novel environment on the day of the testing. The 1h 
period of testing was divided into six 10-minute intervals, to see how the behaviour of a rat was 
changing during the time spent in the Laboras apparatus. Both, adult male and female rats were 
tested in the Laboras test 
The following parameters were automatically evaluated in the Laboras test:  
1) The time spent in locomotion [s]; 
2) The distance travelled (trajectory length) [m]; 
3) The time spent rearing [s]; 
4) The speed of movement [mm/s]. 
 
 
Figure 7: Animal in the Laboras apparatus. 
 
6.2.3 THE SOCIAL INTERACTION TEST  
The Social interaction test (SIT) is used for examining the situation when two animals 
are placed into a familiar open field arena in which neither has established territory and engage 
in social interaction (SI), which include a variety of behaviours excluding aggressive and sexual 
behaviour (File and Hyde 1978). 
In our experiment, the SIT was performed in the open field arena (45x45x30cm) located 




open field on two consecutive days for 10 minutes (File and Hyde 1978). The habituation was 
performed in the same conditions as the experiment. On the third day, a pair of unfamiliar 
animals (each from different cage) of similar weight and the same treatment was tested for 
social interactions. The injection of drug or saline (1.0 ml/kg) was administered s. c. 45 minutes 
prior to SIT (Tab. 3, 4, 5). The behaviour of each pair of animals was recorded for 5 minutes. 
Only adult male rats were tested in the SI test.  
Subsequently, the video recordings were evaluated by using the ODLog program 
(Macropod software). Behaviour was scored by typing pre-set keys on the keyboard of a 
computer. The ODLog software registered the number of pressings and the time in seconds 
between each pressing. Firstly, the total time spent in social interactions (SI; including time 
spent by mutual sniffing, following, climbing over, crawling under and allogrooming) was 
calculated. Secondly, the number (occurrence) and the time spent in various patterns of social 
behaviours, and non-social patterns of behaviour were scored separately to calculate the 
locomotion and exploration for each pair (Tab.1).  
 
Table 1: Ethogram of rat behaviour in SIT test 




Mutual sniffing of 
different body parts 
including genital 
investigation 
Following The pursuit of one animal 
by another 
Climbing over Climbing over the other 
animal 
Crawling under Crawling under the other 
animal 
Allogrooming 
Grooming performed by 
one animal upon the 
another animal 
Non-social behaviour 




regardless whether it 






Figure 8:  Two animals in social interactions. One is performing “mutual sniffing” the other 
one is performing “rearing”. 
 
6.2.4 THE ELEVATED PLUS MAZE TEST  
The Elevated Plus Maze test (EPM) is one of the most widely used models in 
contemporary preclinical research on anxiety. It is based on the natural aversion of the animal 
to high and open spaces and on the fact, that in mazes consisting of open and closed arms, rats 
show higher level of exploration of closed arms and avoidance of open arms (Rodgers et al. 
1997). 
In our experiment, the EPM apparatus consisted of two opposite arms enclosed by 
brown plastic walls (30 cm high) and two opposite open arms and surrounded by transparent 
Plexiglas ledges (0.5 cm high). All the arms were 10 cm wide and joined in the centre of the 
maze (10x10 cm), so the animal could freely move from one arm to another (Fig. 9). The 
apparatus was elevated 40 cm above the floor. The room with the EPM apparatus was 
illuminated by dim lighting (Pometlová et al. 2012). 
All of the animals were handled according to the protocol by Geyer and Swerdlow 
(2007) during three days prior to the EPM test. The animals were moved in their home cages 
into the testing room for at least a 60 minutes acclimation period. The testing was conducted 
between 8:00 a.m. and 13:00 p.m. They were tested in a randomized order, starting the test in 
the central square, facing one of the open arms. An animal received an injection of saline (1.0 
ml/kg) or drug s. c. 45 minutes prior to the test (Tab. 3, 4, 5) and its behaviour was video-
recorded for 5 minutes. In between the individual testing, the maze was cleaned and dried. Both, 




The video recordings were evaluated by using the ODLog program (Macropod 
software).  Four categories were introduced with the parameters chosen based on the study by 
Espejo (1997) modified by Pometlová et al. (2012) (Tab.2).  
 
Table 2: Ethogram of rat behaviour in the EPM 
Category Pattern Description 
Anxiogenic 
behaviour 
Time spent in closed arms (CA) 
[s] 




Time spent in open arms (OA) 
[s] 




Protected stretched approach 
posture   (pSAP) 
[number] 
Forward 
elongation of the 
front quarter of the 
body followed by 
retraction 







All arm entries 
[number] 
Moving from the 
central platform 
into the closed 





Vertical activity in 
the central 




Mobile or quiet 
olfactory 







Figure 9: Animal exploring the open arm of the Elevated Plus Maze. 
 
6.3 COGNITIVE TEST 
6.3.1 THE MORRIS WATER MAZE TEST 
The Morris Water Maze test (MWM) is one of the most widely used ways for testing 
the spatial navigation skills of an animal. The concept behind it is that the animal must learn to 
use distal cues to navigate from the start points around the perimeter of an open arena to locate 
the hidden escape platform (Morris 1984, Stuchlík 2003).  
In our experiment, three test settings were used in this MWM test: the Place Navigation 
test, the Probe test and the Retention Memory test (Schutová et al. 2009). Before each 
experiment the animals were left to acclimatize to the laboratory conditions, in which the 
experiments were performed. Both, adult male and female rats were tested in the MWM test. 
The water maze consisted of a blue circular tank (2m in diameter), filled with water 
(22.5 ± 2.5°C). The maze was divided into 4 quadrants in respect to start positions (north-N, 
south-S, east-E and west-W). A transparent circular platform was placed into NE quadrant of 
the tank, 1 cm below the water surface. The maze was surrounded by various extra-maze cues 
on the walls. The trials were tracked using a video-tracking system EthoVision XT6 (Noldus 





    
Figure 10: Animal in the Morris Water Maze test. From: Animal behaviour research (2015b) 
 
1) The Place Navigation test  
During 6 days of spatial learning (Fig. 11) animals were trained to locate the hidden 
platform within the limit of 60 s. If the animal did not reach the platform within the time limit, 
it was gently guided by the experimenter to the platform. Eight trials per day were performed. 
The position of the platform was the same throughout the period of learning. After each trial, 
the animal remained on the platform for 30 s prior to the next trial to have a chance to orient 
and learn its position in the room. After the trials on each experimental day, the animal received 
the injection of drug or saline (1.0 ml/kg) s. c. and was placed into the home cage (Tab. 3, 4, 
5). The following parameters were evaluated with use of EthoVision program: the latency of 
platform acquisition [s], the distance travelled (the length of the swim-path) [cm], the search 
error (cumulative distance) [cm] and the speed of swimming [cm/s].  
 
2) The Probe test 
During the Probe test (Fig. 11), which was conducted on the 8th day, the platform was 
removed, and the animal was left to swim in the maze for 60 s. The start position in this test 
was for each animal north. The following parameters were recorded: the distance travelled [cm], 
the number of crossing of the quadrant where the platform was located and the duration of 
presence in the quadrant where the platform was located [s], and the speed of swimming [cm/s]. 
After the trials the animal received the injection of drug or saline s. c. and was placed into the 





3) The Memory Recall test 
The memory test was performed on the 12th day (Fig. 11). An animal was expected to 
find the platform located at the same position as during the learning test within 60 s. Each 
animal was subjected to 8 trials. The same parameters were analysed as in the Place Navigation 
test: the latency of platform acquisition [s], the distance travelled (the length of the swim-path) 
[cm], the search error (cumulative distance) [cm] and the speed of swimming [cm/s]. 
 
 
Figure 11: The setting of the Morris Water Maze test with the drug application 
 
6.4 ADULT DRUG TREATMENT - EXPERIMENTAL GROUPS 
Adult female and male rats (PD 60-90) were tested in different tests. From 8 to 16 
animals (or pairs of animals) per group, per sex and per prenatal and adult drug treatment were 
used in each test. The experimental groups are shown in the Table 3. To determine the effect of 
prenatal MA exposure on the sensitivity to related drugs in adulthood the following drugs were 
used (Tab. 4): 
 
1) Methamphetamine (MA)  
- In the CPP test the dose of 5 mg/kg was chosen because it induces similar foetal 
brain drug concentrations and similar behavioural changes to those found in humans 
(Acuff-Smith et al. 1996, Šlamberová et al. 2011b).  
- In the EPM and SIT the effect of MA at a dose of 1 mg/kg was chosen based on 
our preliminary data showing that these doses do not induce stereotypy behaviour that 




- The effect of MA (1 mg/kg) on the spontaneous locomotor activity of females 
and males was not tested in the Laboras test, as this was previously published in a study 
by Schutová et al. (2013) (*).  
- The chronic effect of MA (1 mg/kg) on the on the spatial learning of males was 
not tested in the MWM test, because this was previously published in a study by 
Schutová et al. (2009). The same dose (5 mg/kg) was used to test the chronic effect of 
MA on the spatial learning of females. 
 
2) Drugs with a similar mechanism of action to MA: 
a) Amphetamine (AMP):  
- In the CPP test and the Laboras test the dose of 5 mg/kg was chosen based on a 
work by Timar et al. (1996) showing developed positive place preference conditioning 
by using this dose of AMP.  
- In other tests AMP at a dose of 1 and 5 mg/kg was chosen based on our 
preliminary data showing that these doses do not induce stereotypy behaviour. 1 mg/kg 
of AMP used in the EPM tests was chosen based on a study by Dawson et al. (1995) 
showing an anxiolytic effect of AMP. 
 
b) Cocaine (COC):  
- In all of the tests the dose of 5 mg/kg was chosen based on a work by Heyser et 
al. (1992) showing developed positive place preference conditioning by using this dose 
of COC and at the same time not inducing stereotypy behaviour. 
 
c) MDMA („ecstasy“):  
- In all of the tests the dose of 5 mg/kg was chosen based on a work by Bubeníková 
et al. (2005) showing increased acoustic startle response by using this dose of MDMA 
and at the same time not inducing stereotypy behaviour. 
 
3) Drugs with different mechanism of action to MA  
a) Morphine (MOR):  
- In all of the tests the dose of 5 mg/kg was chosen based on a work by Riley and 
Vathy (2006) showing developed positive place preference conditioning by using this 





- In all of the tests the dose of 2 mg/kg was chosen based on a work by Cheer et 
al. (2000) showing developed positive place preference conditioning by using this dose 
of THC and at the same time not inducing stereotypy behaviour. 
 




DRUG TREATMENT IN 
ADULTHOOD 
SA/SA saline saline 
MA/SA methamphetamine saline 
SA/MA saline methamphetamine 
MA/MA methamphetamine methamphetamine 
SA/AMP saline amphetamine 
MA/APM methamphetamine amphetamine 
SA/COC saline cocaine 
MA/COC methamphetamine cocaine 
SA/MDMA saline MDMA 
MA/MDMA methamphetamine MDMA 
SA/THC saline THC 
MA/THC methamphetamine THC 
SA/MOR saline morphine 














Tab. 4: The dose of drugs used in the tests 
 
 
Tab. 5: Drug treatment regimen in different tests 
TEST TREATMENT 
The Laboras test  Before testing (see 6.2.1) 
The Conditioned Place Preference test  Depended on the testing day (see 6.2.2) 
The Social Interaction test 45 minutes prior to the test (see 6.2.3) 
The Elevated Plus Maze test 45 minutes prior to the test (see 6.2.4) 
The Morris Water Maze test On each day of 12 days period of testing 
(immediately after testing) (see 6.3.1) 
 
6.5 THE OESTROUS CYCLE DETERMINATION 
Every day prior to testing each female was smeared with vaginal lavage. The smear was 
then examined by light microscopy. According to Turner and Bagnara (1976) two phases of the 
oestrous cycle were recognized in the present study: proestrus/oestrus (P/E) with predominance 
of large nucleated and some cornified epithelial cells in the smear; diestrus/metestrus (D/M) 
with predominance of leukocytes in the smear.  
 
6.6 STATISTICAL ANALYSIS 
First, data were tested for normality of distribution. Data with normal (Gaussian) 
distribution were analysed using the Analysis of variance (ANOVA) and presented as [F (N-1, 
TEST Dose (mg/kg) 
 MA AMP COC MDMA MOR THC 
The Conditioned Place 
Preference test 
5 5 5 5 5 2 
The Laboras test - (*) 5 5 5 5 2 
The Social Interaction 
test 
1 1 5 5 5 2 
The Elevated Plus 
Maze test 
1 1 5 5 5 2 
The Morris Water 
Maze test 




n-N) = xx.xx; p˂0.0x], where F is test criterion of ANOVA, N-1 degrees of freedom of groups, 
n-N=degrees of freedom of individual subjects, p is probability level. 
 
THE CONDITIONED PLACE PREFERENCE TEST 
Three-Way ANOVA (factors: prenatal exposure x chamber with drug x sex/oestrous 
cycle) with Repeated Measure (time: before vs. after conditioning) was used to analyse 
differences in the number of entries to chamber and the total time spent in the chamber 
associated with the drug. When appropriate, comparisons between treatment groups were 
conducted by the Bonferroni post-hoc test. Differences were considered significant if p<0.05 
in all statistical analyses. 
 
THE LABORAS 
Three-way ANOVA (factors: prenatal exposure x adult drug treatment x sex/oestrous 
cycle) with Repeated Measure (time: 10-minute intervals) was used to analyse differences. 
When appropriate, comparisons between treatment groups were conducted by the Bonferroni 
post-hoc test. Differences were considered significant if p<0.05 in all statistical analyses. 
 
THE SOCIAL INTERACTION TEST 
Two-way ANOVA (factors: prenatal treatment x acute treatment) was used to analyse 
differences in male rats. When appropriate, comparisons between treatment groups were 
conducted by the Bonferroni post-hoc test. In all tests, the differences were considered 
significant if   
p < 0.05. 
 
THE ELEVATED PLUS MAZE TEST 
Three-way ANOVA (factors: prenatal treatment x acute treatment x sex/oestrous cycle) 
was used to analyse differences. When appropriate, comparisons between treatment groups 
were conducted by the Bonferroni post-hoc test. In all tests, the differences were considered 
significant if p < 0.05. 
 
THE MORRIS WATER MAZE TEST 
The data from the Place Navigation test were analysed by a Three-Way ANOVA 




the test x 8 trials per day). The Probe test data were analysed by a Three-Way ANOVA (factors: 
prenatal exposure x treatment in adulthood x sex/oestrous cycle). A Three-Way ANOVA 
(factors: prenatal exposure x treatment in adulthood x sex/oestrous cycle) with Repeated 
Measure (8 trials per day) was used to analyse the data from the Retention Memory test. The 
Bonferroni post-hoc test was used for post-hoc comparisons. In all tests, the differences were 









































7.1 The Conditioned Place Preference test 
7.1.1 METHAMPHETAMINE 
As shown in Figure 12 A neither males nor females, showed MA-induced increase in 
number of entries to the chamber associated with the drug [F (1,88)=0.09; p=0.87], however 
MA conditioning increased time spent in the chamber associated with the drug [F (1,88)=15.13; 
p<0.01], regardless of sex and prenatal drug exposure. Moreover, males regardless of prenatal 
drug exposure spent more time in the chamber associated with the drug than females [F 
(1,44)=7.85; p<0.01]. 
7.1.2 AMPHETAMINE 
As shown in Figure 12 B neither males nor females, showed AMP-induced increase in 
number of entries to the chamber associated with the drug [F (1,56)=0.42; p=0.52], and in the 
time spent in the chamber associated with the drug [F (1,56)=3.42; p=0.07], regardless of 
prenatal drug exposure.  
7.1.3 COCAINE 
As shown in Figure 13 A neither males nor females, showed COC-induced increase in 
number of entries to the chamber associated with the drug [F (1,56)=0.01; p=0.93], and in the 
time spent in the chamber associated with the drug [F (1,56)=0.04; p=0.84], regardless of 
prenatal drug exposure.  
7.1.4 MDMA 
As shown in Figure 13 B neither males nor females, showed MDMA-induced increase 
in number of entries to the chamber associated with the drug [F (1,56)=1.29; p=0.26]. MDMA 
conditioning increased the time spent in the chamber associated with the drug in females, while 
it decreased in males [F (1,56)=57.93; p<0.05], regardless of prenatal drug exposure. 
Additionally, prenatally-saline exposed females spent more time in the chamber associated with 
the drug than prenatally-saline exposed males [F (1,28)=10.66; p<0.05]. 
7.1.5 MORPHINE 
As shown in Figure 14 A neither males nor females, showed MOR-induced increase in 




conditioning increased the time spent in the chamber associated with the drug [F (1,56)=57.93; 
p<0.05], regardless of sex and prenatal drug exposure. Moreover, saline-exposed females 
preferred the chamber associated with the drug more than saline-exposed males [F (1,56)=8.39; 
p<0.05].   
7.1.6 THC 
As shown in Figure 14 B neither males nor females, showed THC-induced increase in 
number of entries to the chamber associated with the drug [F (1,47)=0.81; p=0.37], and in the 
time spent in the chamber associated with the drug [F (1,47)=0.04; p=0.85], regardless of 























     
  
 
Fig. 12: The effect of  MA (A) and AMP (B) conditioning on the drug-seeking behaviour in 
prenatally MA-exposed and saline (SA)-exposed male and female rats. Lef graph: number of 
entries to the chamber associated with the drug; Right graph: time spent in the chamber 
associated with the drug. Data are presented as differences between experimental day 12 (CPP 
test) and experimental day 1 (pre-exposure). Values are means ± SEM. n (MA)= 8 (males), 16 
(females); n (AMP)= 8.  
**p < 0.01 difference vs. chamber without drug (possitive number means preference and 
negative means avoidance of the chamber associated with the drug).  









     
Fig. 13: The effect of  COC (A) and MDMA (B) conditioning on the drug-seeking behaviour 
in prenatally MA-exposed and saline (SA)-exposed male and female rats. Lef graph: number 
of entries to the chamber associated with the drug; Right graph: time spent in the chamber 
associated with the drug. Data are presented as differences between experimental day 12 (CPP 
test) and experimental day 1 (pre-exposure). Values are means ± SEM. n=8.  
*p < 0.05 difference vs. chamber without drug (possitive number means preference and 
negative means avoidance of the chamber associated with the drug).  












Fig. 14: The effect of  MOR (A)  and THC (B)  conditioning on the drug-seeking behaviour 
in prenatally MA-exposed and saline-exposed male and female rats. Lef graph: number of 
entries to the chamber associated with the drug; Right graph: time spent in the chamber 
associated with the drug. Data are presented as differences between experimental day 12 (CPP 
test)  and experimental day 1 (pre-exposure). Values are means ± SEM. n=3-8.  
*p < 0.05 difference vs. chamber without drug (possitive number means preference and 
negative means avoidance of the chamber associated with the drug). 








7.2 The Laboras test 
7.2.1 METHAMPHETAMINE 
Data with acute MA were published previously by dr. Schutová (Schutová et al. 2013), 
therefore these experiments are not part of the present PhD Thesis. 
7.2.2 AMPHETAMINE 
AMP treatment in adulthood increased in both sexes the time spent in locomotion 
{males: [F (1,33)=15.24; p<0.001]; females [F (1,59)=4.64; p<0.05]} and the distance travelled 
{males: [F (1,33)=20.06; p<0.0001]; females [F (1,59)=5.66; p<0.05]}. AMP treatment did not 
affect speed of movement in males [F (1,33)=0.0003; p=0.99] while decreased in females [F 
(1,59)=5.36; p<0.05] (Table 6 and 7; Figure 15 I). In both genders, prenatal MA exposure 
sensitised the animals to AMP, which was mostly seen in the time spent rearing [F (1,92)=5.21; 
p<0.05]. Specifically, prenatally MA-exposed males [F (1,33)=5.10; p<0.05] and females [F 
(1,59)=4.18; p<0.05] injected with AMP spent more time rearing than prenatally saline-exposed 
rats with the same drug administration. 
7.2.3 COCAINE 
COC treatment in adulthood did not affect behaviour in the Laboras Test in males. In 
females, COC increased the time spent in locomotion [F (1,55)=9.29; p<0.01], the distance 
travelled [F (1,55)=6.97; p<0.05], the time spent rearing [F (1,55)=14.66; p<0.001], as well as 
the speed of movement [F (1,55)=15.62; p<0.001] (Table 6 and 7; Figure 15 II). In females, 
prenatal MA exposure sensitised the animals to COC, which was mostly seen in the time spent 
rearing [F (1,55)=1.89; p<0.05] and the speed of movement [F (1,55)=1.34; p<0.05]. 
Specifically, prenatally MA-exposed females injected with COC spent more time rearing and 
demonstrated increased speed of movement than prenatally saline-exposed rats with the same 
drug administration. 
7.2.4 MDMA 
MDMA treatment in adulthood increased in both sexes the time spent in locomotion 
{males: [F (1,33)=198.15; p<0.0001]; females [F (1,56)=181.70; p<0.0001]}, the distance 
travelled {males: [F (1,33)=81.97; p<0.0001]; females [F (1,56)=96.55; p<0.0001]} and the 
speed of movement {males: [F (1,33)=29.36; p<0.0001]; females [F (1,56)=41.69; p<0.0001]}. 




increased in females [F (1,56)=41.69; p<0.0001] (Table 6 and 7; Figure 16). In addition, 
prenatal MA exposure sensitised females to adult MDMA treatment, when prenatally MA-
exposed females with MDMA treatment spent more time rearing than prenatally saline-exposed 
females [F (1,56)=4.55; p<0.05]. 
7.2.5 MORPHINE 
MOR treatment in adulthood decreased in both sexes the time spent in locomotion 
{males: [F (1,28)=20.29; p<0.0001]; females [F (1,56)=30.21; p<0.0001]}, the distance 
travelled {males: [F (1,28)=15.44; p<0.0001]; females [F (1,56)=27.99; p<0.0001]}, the time 
spent rearing {males: [F (1,28)=41.63; p<0.0001]; females [F (1,56)=76.93; p<0.0001]} and 
the speed of movement {males: [F (1,28)=28.26; p<0.0001]; females [F (1,56)=22.28; 
p<0.0001]} (Table 6 and 7; Figure 17 I). The effect of adult MOR treatment was seen regardless 
of prenatal drug exposure.  
7.2.6 THC 
THC treatment in adulthood did not influence behaviour in the Laboras test in males. In 
females, THC increased the time spent rearing [F (1,58)=2.73; p<0.05] and the speed of 
movement [F (1,58)=3.38; p<0.05] only in a group of prenatally saline-exposed rats (Table 6 




















Fig. 15: The effect of acute AMP (I) and COC (II) treatment on locomotion of male and female 
rats in the Laboras test. A- Time spent in locomotion, B- Distance travelled, C- Time spent 
rearing, D- Speed of movement. Values are means ± SEM. n (males) = 16-20; n (females) = 
25-32. Females AMP/COC vs. females SA (saline) *p<0.05, ** p<0.01; males AMP/COC vs. 





Fig. 16: The effect of acute MDMA treatment on locomotion of male and female rats in the 
Laboras test. A- Time spent in locomotion, B- Distance travelled, C- Time spent rearing, D- 
Speed of movement. Values are means ± SEM. n (males) = 17-20; n (females) = 32. Females 




















Fig. 17: The effect of acute MOR (I) and THC (II) treatment on locomotion of male and female 
rats in the Laboras test. A- Time spent in locomotion, B- Distance travelled, C- Time spent 
rearing, D- speed of movement. Values are means ± SEM. n (males) = 15-22; n (females) = 32-






Table 6: Effect of drugs on behaviour of adult male rats tested in the Laboras test 
↑= increasing drug effect; ↓= decreasing drug effect; P = effect dependent on prenatal drug 
exposure; 0 = no effect 
 
 
Table 7: Effect of drugs on behaviour of adult female rats tested in the Laboras test 
 
↑= increasing drug effect; ↓= decreasing drug effect; P = effect dependent on prenatal drug 
























AMP (5 mg/kg) ↑ ↑ P 0 
COC (5 mg/kg) 0 0 0 0 
MDMA (5 mg/kg) ↑ ↑ 0 ↑ 
MOR (5 mg/kg) ↓ ↓ ↓ ↓ 










AMP (5 mg/kg) ↑ ↑ P ↓ 
COC (5 mg/kg) ↑ ↑ ↑ ↑ 
MDMA (5 mg/kg) ↑ ↑ ↑ ↑ 
MOR (5 mg/kg) ↓ ↓ ↓ ↓ 




7.3 The Social Interaction test 
7.3.1 METHAMPHETAMINE 
Social interaction in total 
Acute MA treatment in adulthood decreased total time spent in SI only in prenatally 
MA-exposed male rats [F (1,28)=8.05; p<0.05] [Figure 18 I (A)] but did not influence 
occurrence of SI [F (1,28)=0.01; p=0.97].  
 
Particular patterns of social interaction 
Mutual sniffing (including genital investigation) 
As shown in Table 8, time of mutual sniffing was decreased after MA treatment only in 
prenatally MA-exposed rats [F (1,28)=17.26; p<0.01]. Occurrence of mutual sniffing was not 
influenced by MA treatment [F (1,28)=0.63; p=0.44].  
Following 
As shown in Table 8, MA treatment did not influence duration of following [F 
(1,28)=0.58; p=0.45]. Occurrence of following was increased by MA treatment only in 
prenatally saline-exposed rats [F (1,28)=12.23; p<0.05]. 
Climbing over 
As shown in Table 8, MA treatment neither influenced duration [F (1,28)=0.00; p=1.00] 
nor occurrence of climbing over [F (1,28)=0.00; p=1.00]. 
Crawling under 
Because of a very low duration and occurrence of crawling under in each group, this 
activity could not be statistically analysed.  
Allogrooming 
As shown in Table 8, MA treatment neither influenced duration [F (1,28)=1.47; p=0.24] 
nor occurrence of allogrooming [F (1,28)=1.92; p=0.18]. 
 
Particular patterns of non-social behaviour 
Locomotion 
As shown in Fig. 18 I (B), MA treatment in adulthood did not influence time of 







As shown in Fig. 18 I (C), MA treatment in adulthood increased occurrence of rearing 
in prenatally SA-exposed rats [F (1,28)=36.89; p<0.001] and prenatally MA-exposed rats [F 
(1,28)=36.89; p<0.05] . 
 
7.3.2 AMPHETAMINE 
Social interaction in total 
AMP treatment in adulthood did not influence occurrence of SI in total between groups 
[F (1,28)=4.63; p=0.04]. Only time spent in SI [F (1,28)=3.23; p=0.08] was decreased after 
AMP treatment in prenatally MA- exposed rats [F (1,28)=3.23; p<0.05] [Figure 18 II (A) ].  
 
Particular patterns of social interaction 
Mutual sniffing (including genital investigation) 
As shown in Table 9, AMP treatment neither influenced duration [F (1,28)=4.4; p=0.59] 
nor occurrence of mutual sniffing [F (1,28)=1.58; p=0.22]. 
Following  
As shown in Table 9, AMP treatment decreased time of following relative to saline-
treated groups [F (1,28)=5.26; p<0.05] regardless of prenatal treatment, and occurrence of 
following was decreased only in the group of prenatally MA-exposed rats [F (1,28)=5.40; 
p<0.05].  
Climbing over 
As shown in Table 9, AMP treatment decreased duration of climbing over relative to 
saline-treated rats [F (1,28)=6.59; p=0<0.05] regardless of prenatal exposure. AMP treatment 
did not influence occurrence of climbing over [F (1,28)=2.10; p=0.16]. 
Crawling under 
Because of a very low duration and occurrence of crawling under in each group, this 
activity could not be statistically analysed.  
Allogrooming 
As shown in Table 9, AMP treatment neither influenced duration [F (1,28)=1.47; 







Particular patterns of non-social behaviour 
Locomotion 
As shown in Fig. 18 II (B), AMP treatment in adulthood increased time of locomotion 
in saline-exposed rats [F (1,28)=27.27; p<0.0001].  
Rearing 
As shown in Fig. 18 II (C), AMP treatment increased occurrence of rearing only in 
prenatally saline-exposed rats [F (1,28)=10.958; p<0.001]. 
 













Duration 26,13±4.67 37.25±4.67** 15.50±4.67 9.13±4.67** 
Occurrence 29.13±3.07 30.75±3.07 28.25±3.07 26.75±3.07 
Following 
Duration 22.00±5.19 17.50±5.19 19.75±5.19 11.88±5.19 
Occurrence 11.50±3.22# 21.38±3.22 25.88±3.22# 13.25±3.22 
Climbing over 
Duration 0.75±0.54 1.5±0.54 1.50±0.54 1.5±0.54 
Occurrence 0.38±0.26 0.75±0.26 0.75±0.26 0.75±0.26 
Crawling under 
Duration LO LO LO LO 
Occurrence LO LO LO LO 
Allogrooming 
Duration 0.25±0.52 1.00±0.52 0 0 
Occurrence 0.25±0.23 0.38±0.23 0 0 
Values are mean ± SEM (n=8 pairs). 
**P<0.01 
#P<0.05 













Fig. 18: The effect of  MA (I) and AMP (II) on the behaviour of male rats in the SIT. A- total 
time spent in SI (social interactions), B- time of locomotion, C- number of rearing, Values are 

















     Duration 
 
26.13 ± 5.78 
 
37.25 ± 5.78 
 
33.88 ± 5.78 
 
20.63 ± 5.78 
Occurrence       29,13 ± 3.04 30,75 ± 3.04 27,13 ± 3.04 25,13 ± 3.04 
Following 
  Duration 22,00 ± 5.07 17,50 ± 5.07 13,13 ± 5.07
 +  3,13 ± 5.07 +  
Occurrence 11,50 ± 2.69 21,38 ± 2.69* 10,13 ± 2.69 10,25 ± 2.69 * 
Climbing over 
    Duration 0.75±0.42 1.5±0.42 0 
+ 0.13 ± 0.42 + 
    Occurrence 0,38 ± 0.3 0,75 ± 0.3 0,75 ± 0.3 1,25 ± 0.3 
Crawling under 
Duration LO LO LO LO 
  Occurrence LO LO LO LO 
Allogrooming 
Duration 0,25 ± 0.52 1.00 ± 0.52 0 0 
Occurrence 0,25 ± 0.23 0,38 ± 0.23 0 0 
Values are mean ± SEM (n=8 pairs). 
*P<0.05 
+ P<0.05 (acute AMP< acute SA) 
LO= “low occurrence” 
 
7.3.3 COCAINE 
Social interaction in total 
COC treatment in adulthood neither influenced time spent in SI [F (1,28)=0.22; p=0.64] 
[Figure 19 I (A)] nor occurrence of SI in total between groups [F (1,28)=1.48; p=0.23].  
 
Particular patterns of social interaction 
Mutual sniffing (including genital investigation) 
As shown in Table 10, COC treatment neither influenced duration [F (1,28)=0.59; 
p=0.45] nor occurrence of mutual sniffing [F (1,28)=0.03; p=0.88]. 
Following 
As shown in Table 10, COC treatment neither influenced duration [F (1,28)=2.68; 






As shown in Table 10, COC treatment decreased duration of climbing over relative to 
saline-treated rats [F (1,28)=6.48; p=0<0.05] regardless of prenatal drug exposure. COC 
treatment did not influence occurrence of climbing over [F (1,28)=2.10; p=0.16]. 
Crawling under 
Because of a very low duration and occurrence of crawling under in each group, this 
activity could not be statistically analysed.  
Allogrooming 
As shown in Table 10, COC treatment neither influenced duration [F (1,28)=1.17; 
p=0.29] nor occurrence of allogrooming [F (1,28)=0.53; p=0.47]. 
 
Particular patterns of non-social behaviour 
Locomotion 
As shown in Fig. 19 I (B), COC treatment in adulthood increased time of locomotion in 
prenatally saline-exposed rats [F (1,28)=28.78; p<0.05] and MA-exposed rats [F (1,28)=28.78; 
p<0.001]. 
Rearing 
As shown in Fig. 19 I (C), COC treatment in adulthood increased occurrence of rearing 






Fig. 19: The effect of  COC (I)  and MDMA (II) on the behaviour of male rats in the SIT. A- 
total time spent in SI (social interactions), B- time of locomotion, C- number of rearing, Values 




Table 10: Effect of COC on particular patterns of social interaction in adult male rats 
Values are mean ± SEM (n=8 pairs). 
+ P<0.05 (acute COC< acute SA) 
LO= “low occurrence” 
 
7.3.4 MDMA 
Social interaction in total 
MDMA treatment in adulthood decreased time spent in SI only in prenatally MA-
exposed rats [F (1,28)=9.65; p<0.05] [Figure 19 II (A)], but did not affect occurrence of SI [F 
(1,28)=0.82; p=0.37].  
 
Particular patterns of social interaction 
Mutual sniffing (including genital investigation) 
As shown in Table 11 time of mutual sniffing was decreased after MDMA treatment 
only in prenatally MA-exposed rats [F (1,28)=14.44; p<0.05]. Occurrence of mutual sniffing 
was not influenced by MDMA treatment [F (1,28)=1.54; p=0.22].  
Following 
As shown in Table 11, MDMA treatment neither influenced duration [F (1,28)=1.17; 













     Duration 26,13±5.72 37,25±5.72 34,13±5.72 38,00±5.72 
Occurrence       29,13±3.53 30,75±3.53 28,00±3.53 33,00±3.53 
Following 
  Duration 22,00±5.18 17,50±5.18 9,13±5.18 13,75±5.18 
Occurrence 11,50±2.57 21,38±2.57 7,38±2.57 11,25±2.57 
Climbing over 
    Duration 0.75±0.04 1.5±0.04 0.25±0.01
+ 0+ 
    Occurrence 0,38±0.42 0.75±0.42 1.75±0.42 0.75±0.42 
Crawling under 
Duration LO LO LO LO 
  Occurrence LO LO LO LO 
Allogrooming 
Duration 0,25±0.52 1.00±0.52 1,00±0.52 0 





As shown in Table 11, MDMA treatment decreased duration of climbing only in 
prenatally MA-exposed rats [F (1,28)=8.53; p=0<0.05]. MDMA treatment did not influence 
occurrence of climbing over [F (1,28)=0.000; p=1.00]. 
Crawling under 
Because of a very low duration and occurrence of crawling under in each group, this 
activity could not be statistically analysed. 
Allogrooming 
As shown in Table 11, MDMA treatment neither influenced duration [F (1,28)=1.47; 
p=0.24] nor occurrence of allogrooming [F (1,28)=1.92; p=0.18]. 
 
Particular patterns of non-social behaviour 
Locomotion 
As shown in Fig. 19 II (B), MDMA treatment in adulthood increased time of locomotion 
in prenatally saline-exposed [F (1,28)=24.79; p<0.05] and prenatally MA-exposed rats [F 
(1,28)=24.79; p<0.05]. 
Rearing 
As shown in Fig. 19 II (C), MDMA treatment in adulthood decreased occurrence of 
rearing in prenatally saline-exposed [F (1,28)=62.65; p<0.001] and prenatally MA-exposed rats 






























Duration 26.13±4.77 37.25±4.77* 15.88±4.77 11.25±4.77* 
Occurrence 29.13±4.03 30.75±4.03 32.00±4.03 37.88±4.03 
Following 
Duration 22.00±4.92 17.5±4.92 21.13±4.92 17.75±4.92 
Occurrence 11.50±2.57 21.38±2.57 20.13±2.57 15.38±2.57 
Climbing over 
Duration 0.75±0.40 1.5±0.40* 0 0* 
Occurrence 0.38±0.27 0.75±0.27 0 0 
Crawling under 
Duration LO LO LO LO 
Occurrence LO LO LO LO 
Allogrooming 
Duration 0.25±0.52 1±0.52 0 0 
Occurrence 0.25±0.23 0.38±0.23 0 0 
Values are mean ± SEM (n=8 pairs). 
*P<0.05 
LO= “low occurrence” 
 
7.3.5 MORPHINE 
Social interaction in total 
As shown in Fig. 20 I (A), acute MOR treatment in adulthood decreased time spent in 
SI relative to groups of saline-treated rats [F (1,28)=9.42; p<0.01], regardless of prenatal drug 
exposure, as well as decreased occurrence of SI, regardless of prenatal exposure [F 
(1,28)=33.92; p<0.05]. 
 
Particular patterns of social interaction 
Mutual sniffing (including genital investigation) 
As shown in Table 12, MOR treatment did not influence duration of mutual sniffing [F 
(1,28)=3.58; p=0.07], but decreased occurrence of mutual sniffing in prenatally saline- [F 







As shown in Table 12, MOR decreased duration of following relative to group of saline-
treated rats [F (1,28)=10.47; p<0.01] regardless of prenatal treatment, as well as decreased 
occurrence of mutual sniffing only in prenatally MA-exposed rats [F (1,28)=14.90; p<0.01].  
Climbing over 
As shown in Table 12, MOR treatment only decreased time in climbing over in 
prenatally MA-exposed rats [F (1,28)=9.61; p<0.05], but did not influence occurrence of 
climbing over [F (1,28)=0.78; p=0.39]. 
Crawling under 
Because of a very low duration and occurrence of crawling under in each group, this 
activity could not be statistically analysed.  
Allogrooming 
As shown in Table 12, MOR treatment neither influenced duration of allogrooming [F 
(1,28)=1.47; p=0.24] nor occurrence of allogrooming [F (1,28)=1.92; p=0.18]. 
 
Particular patterns of non-social behaviour 
Locomotion 
As shown in Fig. 20 I (B), MOR treatment in adulthood decreased time of locomotion 
relative to groups of saline-treated rats [F (1,28)=4.53; p<0.05] regardless of prenatal drug 
exposure. 
Rearing 
As shown in Fig. 20 I (C), MOR treatment decreased occurrence of rearing in prenatally 
saline-exposed [F (1,28)=46.24; p<0.01] and prenatally MA- [F (1,28)=46.24; p<0.0001] 
exposed rats. 
7.3.6 THC 
Social interaction in total 
THC neither influenced time spent in SI [F (1,28)=0.48; p=0.49] [Figure 20 II (A)], nor 








Particular patterns of social interaction 
Mutual sniffing (including genital investigation) 
As shown in Table 13, THC treatment neither influenced duration [F (1,28)=1.34; 
p=0.26] nor occurrence of mutual sniffing [F (1,28)=0.95; p=0.76]. 
Following 
As shown in Table 13, THC treatment did not influence time spent in following [F 
(1,28)=4.33; p=0.05], but  increased occurrence of following in prenatally saline-exposed [F 
(1,28)=36.88; p< 0.001] and MA-exposed rats [F (1,28)=36.88; p< 0.001]. 
Climbing over 
As shown in Table 13, THC treatment increased time in climbing over relative to group 
of saline-treated rats regardless of prenatal treatment [F (1,28)=5.39; p<0.05], as well as 
increased number of climbing over in prenatally saline- [F (1,28)=21.1; p<0.05] and MA- [F 
(1,28)=21.1; p<0.01] exposed rats. 
Crawling under 
Because of a very low duration and occurrence of crawling under in each group, this 
activity could not be statistically analysed.  
Allogrooming 
As shown in Table 13, THC neither influenced duration [F (1,28)=0.92; p=0.35] nor 
occurrence of allogrooming [F (1,28)=0.00; p=1.00]. 
 
Particular patterns of non-social behaviour 
Locomotion 
As shown in Fig. 20 II (B), THC treatment in adulthood did not influence time in 
locomotion [F (1,28)=3.14; p=0.09].   
Rearing 
As shown in Fig. 20 II (C), THC treatment in adulthood did not influence number of 







Fig. 20: The effect of  MOR (I)  and THC (II) on the behaviour of male rats in the SIT. A- 
total time spent in SI (social interactions), B- time of locomotion, C- number of rearing, Values 
are means±SEM. n=8 (pairs). ** p< 0.01, **** p< 0.0001; acute SA vs. acute MOR + p< 0.05, 

















Duration 26.13±5.78 37.25±5.78 23.25±5.78 18.25±5.78 
Occurrence 29.13±2.45# 30.75±2.45**** 18.38±2.45# 12.63±2.45**** 
Following 
Duration 22.00±4.81 17.5±4.81 4.25±4.81++ 4.123±4.81++ 
Occurrence 11.50±2.69 21.38±2.69** 5.13±2.69 7.00±2.69** 
Climbing over 
Duration 0.75±0.41 1.5±0.41* 0 0* 
Occurrence 0.38±0.62 0.75±0.62 0.13 0.63 
Crawling under 
Duration LO LO LO LO 
Occurrence LO LO LO LO 
Allogrooming 
Duration 0.25±0.52 1.00±0.52 0 0 
Occurrence 0.25±0.23 0.38±0.23 0 0 





++ P<0.01 (acute MOR< acute SA) 






































Duration 26.13±5.35 37.25±5.35 43.38±5.35 32.38±5.35 
Occurrence 29.13±2.44 30.75±2.44 32.00±2.44 26.38±2.44 
Following 
Duration 22.00±5.80 17.50±5.80 30.00±5.80 36.63±5.80 
Occurrence 11.50±2.89### 21.38±2.89*** 29.38### 38.63±2.89*** 
Climbing over 
Duration 0.38±0.54 1.5±0.54 2.00±0.54+ 2.75±0.64+ 
Occurrence 0.38±0.62# 0.75±0.62** 2.88±0.62# 3.88±0.62** 
Crawling under 
Duration LO LO LO LO 
Occurrence LO LO LO LO 
Allogrooming 
Duration 0.25±0.52 0.00±0.52 0.00±0.52 0.25±0.52 
Occurrence 0.25±0.24 0.38±0.24 0.25±0.24 0.38±0.24 





+ P<0.05 (acute THC> acute SA) 




















7.4 The Elevated Plus Maze test 
7.4.1 METHAMPHETAMINE 
Anxiolytic and anxiogenic behaviour  
As shown in Figure 21 I (A,B) females with MA treatment spent more time in the OA 
than males with saline treatment [F (1,56)=0.20; p<0.05]. Acute MA treatment decreased time 
spent in the CA in a sex specific manner. Female with MA treatment spent less time in the CA 
than males with the same drug treatment [F (1,56)=1.69; p<0.01]. Number of pSAP was not 
affected by acute MA treatment [F (1,56)=2.25; p=0.14]. The effect of an acute MA treatment 
was seen regardless of prenatal drug exposure.  
Locomotor and exploratory behaviour 
As shown in Figure 21 I (C,D) locomotion was increased in MA-treated females 
{[number of all arm entries [F (1,56)=7.57], number of rearing [F (1,56)=2.86]} compared to 
MA-treated males [number of all arm entries (p<0.001), number of rearing (p<0.05)] and saline-
treated females [number of all arm entries (p<0.05), number of rearing (p<0.05)]. MA treatment 
in adulthood also decreased [F (1,56)= 1.28] time spent sniffing in both, females (p<0.0001) 
and males (p<0.05). The effect of an acute MA treatment was seen regardless of prenatal drug 
exposure. 
7.4.2 AMPHETAMINE 
Anxiolytic and anxiogenic behaviour  
As shown in Figure 21 II (A, B), females with AMP treatment [F (1,56)=1.12] spent 
more time in the OA relative to SA treated females (p<0.05) as well as relative to saline-treated 
males (p<0.01). AMP did not have any effect on time spent in the CA [F (1,56)=1.47; p=0.23]. 
Number of pSAP was decreased in females regardless of prenatal drug exposure [F (1,56)=3.07; 
p<0.05]. The effect of an acute AMP treatment was seen regardless of prenatal drug exposure.  
Locomotor and exploratory behaviour 
As shown in Figure 21 II (C, D) locomotion was increased in AMP-treated females 
{number of all arm entries [F (1,56)=6.95], number of rearing [F (1,56)=2.83] relative to AMP-
treated males [number of all arm entries (p<0.001), number of rearing (p<0.05)] and saline-
treated females [number of all arm entries (p<0.01)]. Time spent sniffing was increased in 
females compared to saline-treated females [F (1,56)=5.92, (p<0.001)]. The effect of an acute 





Anxiolytic and anxiogenic behaviour  
As shown in Figure 22 I (A, B), females with COC treatment [F (1,56)=3.94] spent more 
time in the OA relative to saline-treated females (p<0.001), COC-treated males (p<0.01), as 
well as saline-treated males (p<0.0001). COC did not have any effect on time spent in the CA 
[F (1,56)=0.01; p=0.91]. COC treatment also decreased number of pSAP [F (1,56)=14.43] in 
females relative to saline-treated females (p<0.01) and COC-treated males (p<0.05). The effect 
of an acute COC treatment was seen regardless of prenatal drug exposure.  
Locomotor and exploratory behaviour 
As shown in Figure 22 I (C, D) locomotion was increased in COC-treated females 
{number of all arm entries [F (1,56)=90.33]} relative to saline-treated females (p<0.0001), 
saline-treated males (p<0.0001), as well as COC-treated males (p<0.0001). COC treatment 
decreased time spent sniffing only in males [F (1,56)=10.03; p<0.05]. Number of rearing was 
not affected by acute COC treatment [F (1,56)=1.13; p=0.72]. The effect of an acute COC 
treatment was seen regardless of prenatal drug exposure.  
7.4.4 MDMA 
Anxiolytic and anxiogenic behaviour  
As shown in Figure 22 II (A, B) MDMA treatment did not influence time spent in the 
OA in both genders [F (1,56)=0.15; p=0.69]. Time spent in the CA was increased in females 
after MDMA treatment relative to saline-treated females [F (1,56)=13.31; p<0.01]. Number of 
pSAP was not affected by acute MDMA treatment [F (1,56)=3.43; p=0.07]. The effect of an 
acute MDMA treatment was seen regardless of prenatal drug exposure.  
Locomotor and exploratory behaviour 
As shown in Figure 22 II (C, D) MDMA increased number of all arm entries [F 
(1,56)=5.47; p<0.05] as well as decreased number of rearing [F (1,56)=23.16; p<0.0001] 
regardless of sex. Time spent sniffing was not affected by acute MDMA treatment [F 
(1,56)=0.32; p=0.57]. The effect of an acute MDMA treatment was seen regardless of prenatal 







Fig. 21: The effect of MA (I) and AMP (II) on the behaviour of female and male rats in the 
EPM. A- time spent in OA, B- time spent in CA, C- number of all arm entries, D- number of 
rearing. Values are means±SEM. n=16. Females MA/AMP vs. females SA *p < 0.05, **p < 
0.01;  females MA/AMP vs. males MA/AMP +p < 0.05, ++ p < 0.01, +++ p < 0.001; females 





Fig. 22: The effect of COC (I) and MDMA (II) on the behaviour of female and male rats in 
the EPM. A- time spent in OA, B- time spent in CA, C- number of all arm entries, D- number 
of rearing. Values are means±SEM. n=16. Females COC/MDMA vs. females SA **p < 0.01, 
***p < 0.001, ****p < 0.0001;  females COC vs. males COC ++ p < 0.01, ++++ p < 0.0001; 






Anxiolytic and anxiogenic behaviour  
As shown in Figure 23 I (A, B) MOR treatment did not influence time spent in the OA 
in both genders [F (1,56)=1.28; p=0.26]. MOR treatment [F (1,56)=23.82] increased time spent 
in the CA in males (p<0.01) and females (p<0.05)] relative to saline-treated animals. MOR 
treatment [F (1,56)=3.86] also decreased number of pSAP in females (p<0.0001) and in males 
(p<0.0001) compared to saline-treated females. The effect of an acute MOR treatment was seen 
regardless of prenatal drug exposure.  
Locomotor and exploratory behaviour 
As shown in Figure 23 I (C, D) locomotion was decreased in MOR-treated males {all 
arm entries [F (1,56)=9.03]} relative to saline-treated males [all arm entries (p<0.05)] as well 
as relative to MOR-treated females [all arm entries (p<0.0001)]. Number of rearing was not 
affected by acute MOR treatment [F (1,56)=2.52; p=0.12]. MOR treatment decreased time 
spent sniffing in both sexes [F (1,56)=12.64; p<0.05]. The effect of an acute MOR treatment 
was seen regardless of prenatal drug exposure.  
 
7.4.6 THC 
Anxiolytic and anxiogenic behaviour  
As shown in Figure 23 II (A, B) THC treatment did not influence time spent in the OA 
in both genders [F (1,56)=1.03; p=0.31]. THC treatment increased time spent in the CA both 
genders relative to saline-treated animals [F (1,56)=3.04; p<0.001]. THC treatment [F 
(1,56)=4.54] also decreased number of pSAP in females (p<0.01) and in males (p<0.01) relative 
to saline-treated females. The effect of an acute THC treatment was seen regardless of prenatal 
drug exposure.  
Locomotor and exploratory behaviour 
As shown in Figure 23 II (C, D) THC decreased number of all arm entries [F 
(1,56)=9.20; p<0.05] regardless of sex. Number of rearing [F (1,56)=0.20; p=0.66] and time 
spent sniffing [F (1,56)=0.6; p=0.05] were not affected by acute THC treatment. The effect of 







Fig. 23: The effect of MOR (I) and THC (II) on the behaviour of female and male rats in the 
EPM. A- time spent in OA, B- time spent in CA, C- number of all arm entries, D- number of 
rearing. Values are means±SEM. n=16. Females MOR/THC vs. females SA (resp. males SA 
vs. males MOR/THC) *p < 0.05, **p < 0.01, *** p < 0.001; males MOR vs. females MOR ++ 




7.5 The Morris Water Maze test 
7.5.1  METHAMPHETAMINE 
Data with the effect chronic MA treatment on males were published previously by dr. 
Schutová (Schutová et al. 2009), therefore these experiments are not part of the present PhD 
Thesis. 
 
The Learning test 
Adult MA treatment increased in females the latency [F (1,36)=6.28; p<0.05], the 
distance travelled [F (1,36)=6.33; p<0.05], and the search error [F (1,36)=8.94; p<0.05] relative 
to saline-treated females (Figure 24). The effect of adult MA treatment was only seen in a group 
of prenatally saline-exposed females.   
The Probe test 
Adult MA treatment in females did not influence any of the parameters.  
The Memory Recall test 
Adult MA treatment in females did not influence the distance travelled, the latency and 
the search error.  
The speed of swimming  
Adult MA treatment in females did not influence the speed of swimming in any of the 









Fig. 24: Effect of adult MA treatment on the performance of female rats in the Place 
Navigation test:  A. Latency of platform acquisition B. Distance travelled C. Search error. 
Values are presented as mean ± SEM, n=20. Figure legend means - Sex/Adult treatment females 
MA vs. females MA: *p<0.05. 
 
7.5.2 AMPHETAMINE 
The Learning test 
Adult AMP treatment increased in females the latency [F (1,64)=10.11; p<0.001], the 
distance travelled [F (1,64)=12.79; p<0.001], and the search error [F (1,64)=9.09; p<0.01] 
relative to saline-treated females, as well as to AMP treated males [the distance travelled 
(p<0.05)]  (Figure 25). The effect of adult AMP treatment was only seen in a group of prenatally 
saline-exposed females.   
The Probe test 
In both sexes adult AMP treatment did not influence any of the parameters. 
The Memory Recall test 
Adult AMP treatment increased in females the latency [F (1,64)=6.38; p<0.01] and the 




treated males [the distance travelled (p<0.01), the latency (p<0.01), and the search error 
(p<0.01)]. The effect of adult AMP treatment was seen regardless of prenatal drug exposure.  
The speed of swimming  
In both sexes adult AMP treatment did not influence the speed of swimming in any of 
the tests (Table 14, 15, 16).   
 
 
Fig. 25: Effect of adult AMP treatment on the performance of male and female rats in the 
Place Navigation test:  A. Latency of platform acquisition B. Distance travelled C. Search 
error. Values are presented as mean + SEM, n (female)= 20; n (male)=16. Figure legend means 
- Sex/Adult treatment, females AMP vs. females SA: ** p<0.01, *** p<0.001. 
 
 
7.5.3  COCAINE 
The Learning test 
Adult COC treatment increased in females the latency [F (1,56)=11.65; p<0.01], the 
distance travelled [F (1,56)=14.79; p<0.001], and the search error [F (1,56)=21.64; p<0.0001] 




distance travelled (p<0.01), and the search error (p<0.001)] (Figure 26). The effect of adult 
COC treatment was only seen in a group of prenatally saline-exposed females.  
The Probe test 
In both sexes adult COC treatment did not influence any of the parameters. 
The Memory Recall test 
Adult COC treatment increased in females the latency [F (1,56)=8.37; p<0.01], the 
distance travelled [F (1,56)=13.29; p<0.001], and the search error [F (1,56)=7.82; p<0.01] 
relative to saline-treated females, as well as to COC-treated males [the latency (p<0.01), the 
distance travelled (p<0.001), and the search error (p<0.001)]. The effect of adult COC treatment 
was only seen in a group of prenatally saline-exposed females.   
The speed of swimming  
In both sexes adult COC treatment did not influence the speed of swimming in any of 
the tests (Table 14, 15, 16).   
 
Fig. 26: Effect of adult COC treatment on the performance of male and female rats in the 
Place Navigation test:  A. Latency of platform acquisition B. Distance travelled C. Search 
error. Values are presented as mean + SEM, n=16. Figure legend means - Sex/Adult treatment. 
Females COC vs. females SA: ** p<0.01, *** p<0.001, **** p<0.0001; females COC vs. males 





The Learning test 
Adult MDMA treatment increased in females the latency [F (1,56)=2.93; p<0.001], the 
distance travelled [F (1,56)=8.34; p<0.0001], and the search error [F (1,56)=3.66; p<0.01] 
relative to saline-treated females (Figure 27). The effect of adult MDMA treatment was only 
seen in a group of prenatally saline-exposed females.   
The Probe test 
In females, adult MDMA treatment increased the distance travelled relative to saline-
treated females as well as MDMA treated males [F (1,56)=8.40; p<0.001], and also decreased 
the number of crossing of the quadrant where the platform was located [F (1,56)=88.92; 
p<0.0001] in both sexes. 
The Memory Recall test 
Adult MDMA treatment increased the distance travelled in both sexes [F (1,56)=30.08; 
p<0.0001]. The latency [F (1,56)=2.97; p<0.001] and the search error [F (1,56)=3.10; p<0.01] 
were increased after MDMA treatment only in males relative to saline-treated males. The effect 
of adult MDMA treatment was only seen in a group of prenatally saline-exposed rats.   
The speed of swimming  
Adult MDMA treatment increased the speed of swimming in females compared to saline 
treated females tested in the Learning test [F (1,56)=14.61; p<0.01], the Probe test [F 
(1,56)=8.6; p<0.05], as well as the Memory test [F (1,56)=22.22; p<0.0001] (Table 14, 15, 16). 






Fig. 27: Effect of adult MDMA treatment on the performance of male and female rats in 
the Place Navigation test:  A. Latency of platform acquisition B. Distance travelled C. Search 
error. Values are presented as mean + SEM, n=16. Figure legend means - Sex/Adult treatment. 




The Learning test 
Adult MOR treatment increased in females the latency [F (1, 56)=4.19; p<0.001], the 
distance travelled [F (1,56)=10.86; p<0.0001], and the search error [F (1,56)=5.16; p<0.01] 
relative to saline-treated females (Figure 28). The effect of adult MOR treatment was only seen 
in a group of prenatally saline-exposed females.   
The Probe test 
In both sexes adult MOR treatment did not influence the number of crossing and 
duration of presence in the quadrant where the platform was located. Adult MOR treatment 
increased the distance travelled in females compered to MOR treated males [F (1,56)=8.68; 






The Memory Recall test 
Adult MOR treatment increased in females the latency [F (1,56)=0.10; p<0.05], the 
distance travelled [F (1,56)=2,37; p<0.001], and the search error [F (1,56)=1.63; p<0.05] 
relative to saline treated females. The effect of adult MOR treatment was only seen in a group 
of prenatally saline-exposed females.   
The speed of swimming  
Adult MOR treatment decreased speed of swimming in males relative to MOR treated 
females in The Learning test [F (1,56)=12.72; p<0.001] and in the Probe test [F (1,56)=8.81; 
p<0.01]. Additionally, adult MOR treatment increased the speed of swimming in females 
relative to saline-treated females tested in the Learning test [F (1,56)=12.72; p<0.01], as well 
as in the Memory test [F (1,56)=7.94; p<0.01] (Table 14, 15, 16). There was no interaction 
between prenatal exposure and adult drug treatment. 
 
 
Fig. 28: Effect of adult MOR treatment on the performance of male and female rats in the 
Place Navigation test:  A. Latency of platform acquisition B. Distance travelled C. Search 
error. Values are presented as mean + SEM, n=16. Figure legend means - Sex/Adult treatment. 






The Learning test 
Adult THC treatment increased in females the latency [F (1,56)=9.39; p<0.001], the 
distance travelled [F (1,56)=18.16; p<0.0001], and the search errors [F (1,56)=10.57; p<0.001] 
relative to saline-treated females, as well as to THC-treated males [the distance travelled 
(p<0.01) ] (Figure 29). The effect of adult THC treatment on the duration and the search error 
was only seen in a group of prenatally saline-exposed females.   
The Probe test 
In both genders adult THC treatment did not influence the number of crossing of the 
quadrant where the platform was located. In females adult THC treatment increased the distance 
travelled [F (1,56)=10.58; p<0.01], as well as decreased the duration of presence in quadrant 
where the platform was located [F (1,56)=6.78; p<0.05] relative to THC-treated males, 
regardless of prenatal drug exposure. 
The Memory Recall test 
Adult THC treatment increased in females the latency [F (1,56)=1.05; p<0.0001], the 
distance travelled [F (1,56)=9.31; p<0.001] and the search error [F (1,56)=5.06; p<0.05] relative 
to saline-treated females, as well as to THC-treated males [the distance travelled (p<0.001)] 
and the search error (p<0.01)]. The effect of adult THC treatment on the duration and the search 
error was only seen in a group of prenatally saline-exposed females.   
The speed of swimming  
Adult THC treatment decreased speed of swimming in males relative to THC treated 
females in The Learning test [F (1,56)=14.48; p<0.001], in the Probe test [F (1,56)=10.87; 
p<0.01], as well as in the Memory test [F (1,56)=18.75; p<0.0001]. Additionally, adult THC 
treatment increased speed of swimming in females compared to saline treated females tested in 
the Learning test [F (1,56)=14.48; p<0.01] and in the Memory test [F (1,56)=18.75; p<0.001] 






Fig. 29: Effect of adult THC treatment on the performance of male and female rats in the 
Place Navigation test:  A. Latency of platform acquisition B. Distance travelled C. Search 
error. Values are presented as mean + SEM, n=16. Figure legend means - Sex/Adult treatment. 
























         
 
 
Values are mean ± SEM (n=16-20). 
**    P<0.01   (females drug vs. females SA) 














Values are mean ± SEM (n=16-20). 
*    P<0.05   (females drug vs. females SA) 













Values are mean ± SEM (n=16-20). 
**      P<0.01      (females drug vs. females SA) 
***    P<0.001    (females drug vs. females SA) 
****  P<0.0001  (females drug vs. females SA) 
++++ P<0.0001  (males drug vs. females drug) 
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7.6 THE PRENATAL DRUG EFFECT 
7.6.1  THE LABORAS TEST 
Only in two experiments the main effect of prenatal MA exposure was shown and this 
effect was only seen in females. In the COC experiments, females rats exposed to MA 
prenatally demonstrated increased time spent in locomotion [F (1,55)=5.29; p<0.05], longer 
distance travelled [F (1,55)=6.06; p<0.05], increased time spent rearing [F (1,55)=7.31; 
p<0.01], as well as increased speed of movement [F (1,55)=4.99; p<0.05], when compared to 
saline-exposed females, regardless of adult drug exposure. In the MOR experiments females 
rats exposed to MA prenatally demonstrated increased time spent in locomotion [F (1,56)=4.78; 
p<0.05], longer distance travelled [F (1,56)=4.19; p<0.05], and increased time spent rearing [F 
(1,56)=4.19; p<0.05], when compared to saline-exposed females. 
7.6.2 THE SOCIAL INTERACTION TEST 
In males, prenatal MA exposure neither influenced social interactions {time spent in SI 
[F (1,28)=0.69; p=0.4] and occurrence of SI [F (1,28)=3.36; p=0.07]}, nor influenced the time 
spent in locomotor activity [F (1,28)=0.64; p=0.43] and the number of rearing [F (1,28)=3.69;  
p=0.05].  
7.6.3  THE ELEVATED PLUS MAZE TEST 
Prenatal MA exposure did not influence any parameters of anxiogenic and anxiolytic 
behaviour.  
7.6.4 THE MORRIS WATER MAZE TEST 
Prenatal MA did not influence any parameters of the Learning, Probe and Memory Recall 
test.   
 
7.7 THE EFFECT OF THE GONADAL HORMONES 
7.7.1 THE CONDITIONED PLACE PREFERENCE TEST 
Results from the CPP showed that females were more active than males {higher number 





7.7.2 THE LABORAS TEST  
Results from the Laboras test demonstrated that females in P/E were more active than 
males {spent more time in locomotion [F(2,87)=12.93, p<0.0001], travelled a longer distance 
[F(2,87)=15.26, p<0.0001], spent more time rearing [F(2,87)=12.63, p<0.0001], and were faster 
in walking [F(2,87)=13.29, p<0.0001]}, regardless of the acute drug treatment and prenatal 
exposure. Additionally, females in P/E were more active than females in M/D {spent more time 
in locomotion [F(1,55)=6.07, p<0.05], travelled a longer distance [F(1,55)=3.75, p<0.05], spent 
more time rearing [F(1,55)=5.67, p<0.05], and were faster in walking [F(1,55)=3.84, p<0.05]}. 
7.7.3  THE ELEVATED PLUS MAZE TEST 
Results from the EPM demonstrated that females in P/E were less anxious and more 
active than males {spent more time in open arms [F(2,52)=4.83, p<0.05], less time in closed 
arms [F(2,52)=5.36, p<0.01], and showed higher number of all arm entries [F(2,52)=38,13, 
p<0.0001]}, regardless of the acute drug treatment and prenatal exposure. However, females in 
P/E did not differ in locomotion and anxiety to females in M/D {time in open arms 
[F(1,24)=0.05, p=0.83], time spent in closed arms [F(1,24)=0.47, p=0.50], and all arm entries 
[F(1,24)=0.08, p=0.93]}. 
7.7.4 THE MORRIS WATTER MAZE TEST 
Results from the MWM did not show any differences in the learning abilities between 
males and females as the Learning test proceeded {the latency [F(5,280)=1.27, p=0.28], the 
distance [F(5,280)=0.47, p=0.79], the search error [F(5,280)=1.28, p=0.27]}. However, the 
Memory Recall test revealed a weaker memory recall of females when compared to males 
{females swam longer distance [F(1,56)=10.60, p<0.01], for longer time [F(1,56)=8.03, 
p<0.01] and showed higher search error [F(1.56)=8.76, p<0.01]}. On the Probe test females 
also spent less time in the quadrant where the platform was located than males [F(1,56)=9.62, 
p<0.01]. As far as the speed of swimming is concerned, females in different phases of the 
oestrous cycle did not differ to males {in the Probe test [F(2,56)=0.48, p=0.62] and in the 









8 THE SENSITISATION  
In this study, using different behavioural models, we tested the hypothesis that prenatal 
MA exposure sensitises animals to the effect of various drugs administrated to adult rats. We 
can summarize by saying that a sensitising effect associated with prenatal MA exposure to the 
psychostimulant effect of some drugs was found, which was mostly observed as increased 
spontaneous locomotor activity. Specifically, in the Laboras test, prenatally MA-exposed 
animals demonstrated increased exploration after AMP treatment in adulthood compared to 
prenatally saline-exposed animals with the same adult treatment. Moreover, in females, prenatal 
MA exposure sensitised animals to the psychostimulant effects of AMP, COC, and MDMA. 
We did not find any interaction between prenatal MA exposure and adult drug treatment with 
regard to active drug-seeking behaviour, which was tested using the CPP test. An interaction 
was found in the SIT, in which prenatally MA-exposed males demonstrated decreased social 
interactions after MA, AMP, and MDMA treatment, compared to saline-exposed animals. 
Prenatal MA exposure did not sensitise animals to the anxiogenic and anxiolytic effect of drugs 
administrated just prior to testing in the EPM, nor to the effect of chronic administration of 
these drugs on spatial learning, tested using the MWM test.  
To expand the existing knowledge regarding sensitisation, different behavioural test 
models were used in the present study. Specifically, tests that are traditionally used for testing 
sensitisation, i.e., the Laboras test for examining augmented locomotor activity produced by 
repeated drug administration, and the CPP test for examining active drug-seeking in animals. 
The other tests included the EPM test (for examining anxiety-related behaviour), the SIT test 
(for examining social interactions of two individuals), and the MWM test (for examining 
cognitive functions in terms of spatial learning). These tests were used based on the studies of 
Schutová et al. (2009), Schutová et al. (2010) and Šlamberová et al. (2008) that showed the 
sensitising effect of prenatal MA not only to the psychomotor-stimulant effect of MA, but also 
to other drug' effects.   
 
8.1 MA and drugs with similar mechanism of action as MA 
Results from the Laboras test showed that in both males and females, prenatal MA 
exposure induced sensitisation, but only to the psychostimulant effect of an acute dose of AMP, 




exposed males and females compared to saline-exposed animals demonstrated increased time 
spent rearing after AMP treatment. In our present study, the effect of an acute MA was not 
tested, as we wanted to confirm a study of Schutová et al. (2013), in which male rats prenatally 
exposed to MA demonstrated increased sensitivity to adult MA treatment by increased rearing, 
and in female rats by increased distance travelled. Other studies have demonstrated increased 
sensitivity to MA in rats exposed to MA in utero (using the Laboras test) (Šlamberová et al. 
2011c) as well as several seizure models (Šlamberová et al. 2008, Šlamberová et al. 2010b). 
Moreover, Bubeníková-Valešová et al. (2009) showed increased DA release in the NAc after 
MA challenge in adult rats prenatally exposed to the same drug, which correlated with increased 
time spent rearing and locomotion. In contrast to the results from the Laboras test, our data from 
the CPP test did not demonstrate any significant increase in active AMP-seeking behaviour 
induced by prenatal MA exposure. Our results, which showed no sensitising effect resulting 
from prenatal MA exposure on AMP-seeking in adulthood, are in agreement with a study by 
Šlamberová et al. (2011b) using the CPP test and MA administrated to male rats. According to 
these results and our results, we suggest that although prenatal MA can sensitise animals to the 
psychostimulant effect of acute MA and AMP, it does not necessarily increase active drug 
behaviour relative to these drugs.   
Only females, in the Laboras test, displayed sensitisation induced by prenatal MA 
exposure to COC and MDMA. Specifically, prenatally MA exposed females compared to 
saline-exposed females, demonstrated increased time spent rearing movements after COC and 
MDMA treatment. The most likely explanation of this effect, which was found in females but 
not in males, might be based on sexual dimorphism relative to brain neurotransmitter system 
development. It has been said by Vathy et al. (1993, 1995) that prenatal drug exposure affects 
the brain of females and males differently (particularly in terms of changes in neurotransmitter 
levels), and as a result, females might be more sensitive when exposed to other drugs in 
adulthood. Our data showing sex differences in sensitisation are in agreement with studies of 
Melnick and Dow-Edwards (2001) and Peris et al. (1992) suggesting that these sex differences 
correspond with dopamine activity. Moreover, Bubeníková-Valešová et al. (2009) showed 
sensitisation induced by prenatal MA exposure to MA challenge in adult male rats 
corresponding with DA levels in the nucleus accumbens. We suggest more studies to be done 
to see whether there are also sex differences in the DA concentration after treatment with 
different drugs that would support our finding showing sex differences in the sensitisation. 
Additionally, the CPP test did not reveal any sensitising effects, related to sex, of prenatal MA 




data” in females, revealed avoidance than preference for the chamber associated with COC in 
animals with prenatal MA exposure. These results indicate some kind of tolerance to COC 
treatment developed after MA exposure in utero. We could only compare our results with the 
results of Peltier et al. (1996), who demonstrated tolerance to the reinforcing effects of COC 
induced by chronic treatment with MA.  
Results showing some kind of interaction between prenatal MA exposure and an acute 
psychostimulant treatment in the other tests can be described as follows. In the SIT, although 
there was no interactions found in locomotor activity (non-social behaviour), an interesting 
result was found with regard to social behaviour in groups of males treated in adulthood with 
MA, AMP, and MDMA. Specifically, prenatally MA-exposed males with acute MA, AMP, and 
MDMA treatments showed decreased time spent in social interactions compared to saline-
exposed animals treated in adulthood with the same drugs. It appears, that prenatal MA 
sensitised the animals, such that they have reduced social behaviour when administrated these 
drugs as adults. As far as we know, there are no studies investigating possible sensitising effects 
of prenatal MA exposure on disturbances in social interactions after drug treatment later in 
adulthood. There was a study that investigated prenatal or perinatal exposure to other drugs in 
rats relative to either decreased social interactions or increased reactivity to stress (Molina et 
al. 1994). Molina et al. (1994) also demonstrated that rats prenatally exposed to COC showed 
increased behavioural responsiveness to stress in adulthood. However, we did not test females 
(using the SIT), because it has been shown (Šlamberová et al. 2011a) that MA at a dose of 1 
mg/kg decreased different types of social interaction in both sexes. That is why we could not 
be sure, if there would be some sensitising effect of prenatal MA in females. Compared to 
results from the SIT, we did not find any interaction between prenatal drug exposure and acute 
drug treatment relative to anxiety related behaviour using the EPM test, which is another test 
for anxiety. We suggest, that the discrepancies might indicate methodological differences 
between tests that measure anxiety, rather than the effect of the drugs per se. Finally, when 
analysing data from the MWM, we did not find any sensitising effect of prenatal MA relative 
to any of the tested drugs with regard to learning abilities in adult female or male rats, which is 
in agreement with a study by Schutová et al. (2009) on males showing that prenatal MA 






8.2 Drugs with different mechanism of action than MA 
As far as the sensitising effect of prenatal MA exposure relative to adult MOR and THC 
treatment is concerned, we did not find any significant result, in the CPP test and in the Laboras 
test. To the best of our knowledge, there have been no studies investigating increased sensitivity 
to MOR after prenatal MA exposure. Vela et al. (1998) demonstrated that females prenatally 
exposed to THC during the gestation and lactation period exhibited an increase in the rate of 
MOR self-administration. On the other hand, prenatal MOR exposure was not shown to affect 
MOR self-administration in a study by Riley and Vathy (2006); however there was an increase 
in MOR-conditioned place preference in the study by Gagin et al. (1997). Interestingly, in the 
Laboras test, prenatally saline-exposed females demonstrated increased time spent rearing, as 
well as increased velocity, after THC treatment compared to prenatally MA-exposed females. 
Such results indicate tolerance to THC induced by prenatal MA exposure in females, rather 
than sensitisation. Unfortunately, there are no studies examining the long-term effect of prenatal 
MA on sensitisation to THC in females, which could be compared to our results.   
As far as the other test was concerned, there was no interaction found in the social 
behaviour tested using the SIT, in anxiety related behaviour tested using the EPM test, or in the 
spatial learning abilities tested using the MWM test. One possible explanation suggested by us, 
is prenatal MA does not sensitise the animal to the effect of drugs with different mechanisms 
of action; however, more studies need to be done to clarify this problem.  
Findings from our present study have extended the view of t of sensitisation, developed 
to different drugs, after prenatal MA exposure. It seems that animals exposed to MA prenatally 
demonstrate increased sensitivity to MA as well as to drugs with similar mechanisms of action; 
however, drug effects depend on the behavioural test performed. Moreover, our results also 
demonstrated that females are more vulnerable to the effect of prenatal MA exposure in terms 
of developed sensitisation to other psychostimulants administrated in adulthood. However, it is 
obvious that more tests are needed; we suspect that our results, which show different 
interactions between prenatal MA exposure and drug treatment in adult rats are probably based 
on different neurotransmitter pathways. Nestler (2005) has suggested that at least three systems 
play a key role in development of sensitisation. Firstly, chronic exposure to any of several of 
commonly abused drugs impairs the VTA-NAc pathway, which was demonstrated by 
sensitisation of the DA system, with a greater increase in DA transmission occurring in response 
to the drug. Secondly, chronic exposure to drugs reduces the basal activity of the frontal cortical 




impulsivity. Thirdly, hyperfunction of corticotropin releasing factor systems and their 
connections to the amygdale have been shown to mediate the negative emotional symptoms 
that occur during drug withdrawal. At the molecular and cellular level, there has been an 
increase interest regarding in changes in NMDA and AMPA glutamate receptors in DA neurons 
after chronic drug use (Šlamberová et al. 2014, Thomas and Malenka 2003). It is believed that 
these receptors are involved in long-term potentiation, which is a key process associated with 
memory and learning consolidation in the hippocampus (Pu et al. 2002). Consequently, similar 
molecular and cellular mechanisms utilized by the brain to form normal memories and 
addiction-related memories might play a key role in the reactivity to drugs later in life. The 
situation relative to development of sensitisation after prenatal drug exposure is even more 
unclear and our results raised important questions that deserve further attention. 
 
9. EFFECT OF DRUGS ON BEHAVIOUR 
9.1 Effect of drugs on active drug-seeking behaviour in the Conditioned Place 
Preference test 
In the CPP test the effect of drug treatment on active drug seeking behaviour of 
prenatally MA-exposed adult male and female rats was examined. The results demonstrated 
that MA increased time spent in the chamber associated with MA in both, females and males 
(independently of prenatal exposure). This result is in agreement with the CPP study on males 
by Šlamberová et al. (2011c). Following conditioning with MA at different dozes (0.25, 0.5, or 
1 mg/kg), preference for the MA-paired chamber compared to the saline-paired chamber was 
also found in a study by Berry et al. (2012).There have also been other studies demonstrating 
MA conditioning in mice (Bryant et al. 2012) as well as in humans (Mayo et al. 2013). 
Moreover, in our study, males after MA conditioning spent more time in the drug-paired 
chamber than females, which is in contrast to the results of a study by Chen et al. (2003), who 
found that gonadal hormones in females (the oestradiol specifically) facilitates MA-induced 
conditioning. In their study, MA-induced conditioning was shown to be increased in 
gonadectomised female mice after pre-treatment with the oestradiol compared to 
gonadectomised male mice. 
Neither AMP nor COC conditioning, lead to drug-seeking in females or males. Contrary 
to our results, COC has been previously shown to induce an increase in drug-seeking after 




caused by the use of different models compared our study. Since Chen et al. (2003) used a COC 
dose of 5 mg/kg on mice, our use of the same dose COC on rats might have caused a weaker 
response. Moreover, Russo et al. (2003) showed in their study using male rats, that COC 
conditioning induces increased drug-seeking only when administrated at a dose of at least 10 
mg/kg. Other studies have demonstrated that not only the model and dose of drug used for 
conditioning, but also the stage of development at which the drug is administrated plays an 
important factor. Adolescent rats were shown to be more sensitive to the conditioned rewarding 
properties of COC, MA, and AMP than adult rats exposed to the same dose of drug (Shahbazi 
et al. 2008, Zakharova et al. 2009).  
The present data also demonstrated sex-dependent effects of MDMA conditioning. 
While males showed an aversion to the drug, seen as decreased time spent in the drug-paired 
chamber, females showed the opposite effect, by spending more time in the chamber. These 
completely different results of MDMA conditioning on males and female were rather 
surprising, and difficult to compare to other available MDMA studies with ambiguous results 
on the CPP test. Comparing preference/aversion for the drug-paired chamber required results 
from studies that used comparable designs to our study. For example, increased drug-seeking 
after MDMA conditioning was shown in adolescent rats (at a dose of 2.5 mg/kg), as well as in 
adult rats (at a dose of 5 mg/kg) (Catlow et al. 2010). There has been only one study in which 
MDMA conditioning decreased in males; however, in this study animals were administrated to 
a neurotoxic dose of MDMA (20 mg/kg) prior to the MDMA CPP testing (Schechter 1991). A 
possible explanation for the gender differences in drug-searching activity after MDMA 
conditioning might be based on gender differences in neurotransmitter systems, specifically, a 
5-HT. MDMA has been shown to be a strong 5-HT releaser and females tend to show greater 
5-HT activity than males (Carlsson and Carlsson 1988, Verrico et al. 2007). 
Increased drug-seeking after MOR conditioning in both, females and males was found 
in both prenatally exposed groups, and manifested as increased time spent in the chamber 
associated with MOR. These results are in accordance with many other reports that found  
rewarding properties of MOR on the CPP test (Martin et al. 2000, Mueller et al. 2002), and also 
self-administration tests (Bozarth and Wise 1981). Mueller et al. (2002) showed preferences 
following conditioning with MOR at the same dose as we used (5 mg/kg), and they found that 
MOR-induced CPP persisted for at least 12 weeks. As far as we are aware there is no study 
showing increased drug-seeking behaviour after MOR conditioning in females, so our results 
provide new information to this research field. We did not find any preferences after THC-




with drug. These results agree with the results of the study of Cheer et al. (2000) who also found 
an aversion to the chamber associated with THC (at a dose of 1.5 mg/kg) as well as to the 
chamber paired with a synthetic cannabinoid agonist. These findings are also supported by a 
study from Leite and Carlini (1974) that showed that rats fail to self-administer cannabinoids. 
Cheer et al. (2000) suggested one possible explanation of this aversive effect of cannabinoids. 
They claimed that the rewarding effects of cannabinoids might be masked by their anxiogenic 
effects, which was shown in a previous study (Onaivi et al. 1990). In addition, our present 
results from the EPM test support this hypothesis.  
9.2 Effect of drugs on the locomotor activity using the Laboras test  
Using the Laboras test, we tested the effect of acute drug treatment on the behaviour of 
prenatally MA-exposed adult male and female rats in an unknown environment. Our results 
from the Laboras test showed that acute AMP and MDMA increased the time spent in 
locomotion and the distance travelled, which was comparable in both sexes. AMP (similarly to 
MA) and MDMA, have been repeatedly shown to increase locomotor activity (Milesi-Halle et 
al. 2007, Páleníček et al. 2005, Shoblock et al. 2003b, Schutová et al. 2010, Schutová et al. 
2013, Šlamberová et al. 2011c). Although, in our study, both drugs (AMP and MDMA) led to 
equally increased locomotion activity in both sexes, other studies have shown a stronger effect 
on females than males (Milesi-Halle et al. 2007, Páleníček et al. 2005). Interestingly, after a 
detailed analysis of our data we could see that while AMP increased locomotion and distance 
travelled only at the beginning of the Laboras test, the effect was no longer significant after the 
40th minute of testing, while the increased effect of MDMA on these parameters lasted the entire 
hour of testing. It is possible that the dose of 5 mg/kg of MDMA was too high to return the 
increased locomotion to the controls prior to the end of the test one hour test period; this is 
plausible since the effect of MDMA on locomotion has been shown to be dose specific 
(Páleníček et al. 2005). While velocity was increased after MDMA in both genders, AMP did 
not have any effect on males, and had a decreasing effect on females. This decreasing effect 
shows, in contrast to previously mentioned studies, the locomotor-stimulating effect of AMP, 
which might have been caused by the fact that females without any drug treatment show an 
increased interest in novel environment compared to AMP-treated females or males.  
The effect of adult COC treatment was sex-specific. COC increased all parameters of 
locomotor activity in the Laboras test, but only in females. Because there have been more 
studies showing increased behavioural activities after COC treatment in males (Broderick et al. 




there have also been studies reporting greater behavioural effects of COC on females compared 
to males (van Haaren and Meyer 1991, Walker et al. 2001). A detailed analysis of our data 
revealed that in females the increased activity induced by COC was not seen until the 20th 
minute of the test, while in males, increased time spent in locomotion and rearing were not seen 
until the 40th minute of the test. It is therefore possible that the COC-stimulating effect arises 
later, specifically, even later in males than in females, and thereby females might be more 
sensitive than males to COC administration. Additionally, the different effect of COC treatment 
on males and females could also be linked to the gender differences in the 5-HT system, which 
has been shown to be more expressed in females (Carlsson and Carlsson 1988), and to the fact, 
that 5-HT has been suggested as a contributor to the behavioural effects of COC (Rothman and 
Baumann 2003).  
As mentioned before, differences in 5-HT and DA neurotransmission might explain 
observed gender differences in the locomotor stimulant effects of the psychostimulants used in 
our study. Gender differences in the brain concentrations of 5-HT have been previously 
demonstrated, with females showing greater 5-HT activity (Carlsson and Carlsson 1988, 
Verrico et al. 2007). Additionally, greater DA and 5-HT sensitivity to various stimuli have also 
been reported in females (Robinson et al. 1980). It has been shown, that ovarian hormones play 
an important role in setting the sensitivity and reactivity to these two neurotransmitter pathways. 
Several studies have reported that the oestradiol plays an important role in inducing increased 
AMP-stimulated DA release in OVX females. Other studies have shown attenuated SERT and 
DAT concentrations in OVX females, and these changes were prevented by the oestradiol 
treatment. 
MOR decreased all parameters of locomotor activity, without regard to prenatal 
exposure or sex. There are studies that have shown dose dependent effects relative to acute 
MOR treatment on locomotor activity (Babbini and Davis 1972, Patti et al. 2005, Vezina and 
Stewart 1987). For example, Babbini and Davis (1972) demonstrated that a single injection of 
low-doses of MOR (1.25, 2.5, and 5 mg/kg) administrated intraperitoneally had an excitatory 
effect, while higher doses (≥10 mg/kg) had an inhibitory effect. In our study we only used MOR 
at a dose of 5 mg/kg; however, even this dose inhibited locomotor activity. Because we did not 
use lower doses, we were not able to evaluate if there was a dose-dependent effect of MOR on 
locomotion. It should be noted that the locomotor-stimulating effect of MOR, shown by Babbini 
and Davis (1972), was demonstrated 8 hours after the MOR administration, while in our study 
the animals were tested right after drug administration. THC treatment did not have any effect 




motor activity-decreasing effects (Hernandez-Tristan et al. 2000, Schramm-Sapyta et al. 2007). 
The observed differences might have been caused by different doses of THC used in our study 
(2 mg/kg) and the studies by Schramm-Sapyta et al. (2007) and Hernandez-Tristan et al. (2000) 
that used 5 mg/kg. 
9.3 Effect of drugs on the social behaviour using the Social Interaction test 
In the SIT the effect of acute drug treatment on social interaction, as well as locomotor 
activity of prenatally MA-exposed adult male rats was examined. All psychostimulant drugs 
tested using the SIT, apart from COC, induced disturbances in social behaviour. Particularly, 
results from the SIT showed that acute MA, AMP, as well as MDMA decreased total time spent 
in social interactions (SI), especially in the group of prenatally MA-exposed male rats. In our 
study we used 1 mg/kg as the acute dose of MA, which did not induce any stereotypical 
behaviour; however, nonetheless, the dose had still been shown to decrease SI (Šlamberová et 
al. 2010a). There are also other studies that have shown decreases in SI after treatment with 
MA (Arakawa 1994), AMP (Tikal and Benešová 1972), and MDMA (Bull et al. 2004) in a 
dose-dependent manner. It should be noted, that in the present study [in contrast to the study of 
Šlamberová et al. (2010a)] the effect of acute drug treatment on total time spent in SI was 
examined in animals exposed to MA in utero, and prenatal exposure seemed to have an impact, 
since the time spent in SI was decreased more in prenatally MA-exposed group than in saline-
exposed animals. Our explanation of this result was discussed in more detail Chapter 8 
(Sensitisation). Furthermore, we did not find any effect of acute drug treatment for MA, AMP, 
and COC, with regard to particular patters of SI (specifically, mutual sniffing, allogrooming, 
and climbing over, were not affected). Only AMP treatment decreased both time and occurrence 
of following, while time spent in climbing over was decreased after both MDMA and AMP 
treatment. However, based on these patterns of SI associated with acute drug treatment, no 
definitive drug effects can be concluded.  
As far as the effect of the tested psychostimulants on the patterns of non-social activity 
was concerned, our results showed that AMP, COC, and MDMA increased the time spent in 
locomotion, while MA, AMP, and COC also increased the occurrence of rearing, which are in 
agreement with other studies that have shown increased locomotion after treatment with 
psychostimulants (Bull et al. 2004, Šlamberová et al. 2015). It has been previously shown that 
environmental conditions play a role in social and non-social behaviour, especially, familiarity 
of the open field arena (File and Hyde 1978, Šlamberová et al. 2010a). Šlamberová et al. 




activity. Because the animals in our present study underwent 2 days of habituation to the open 
field arena, we could exclude the effect of a novel environment, and conclude that the any 
increased locomotion would be linked to the effect of the tested psychostimulants. We also 
noted a correlation between social and non-social behaviour [similar found in a study by 
Šlamberová et al. (2010a)], where an increase in time spent in locomotion correlated with a 
decrease in SI in rats treated with MA. This trend was found in our present study, showing 
increased locomotor activity and decreased SI in animals with MA, AMP, and MDMA 
treatment. We suggest that the locomotor-stimulating effect of these drugs might mask the SI-
related behavioural effects, and thus we did not see any drug effects on the particular patterns 
of SI. 
COC treatment neither influenced the total time spent in SI, nor particular patterns of 
SI. On the other hand, treatment with this drug increased the occurrence of rearing as well as 
the time spent in locomotion. The COC locomotor-stimulating effect has been previously 
discussed and is similar to that seen in other studies (Broderick et al. 2003, De La Garza and 
Cunningham 2000). Our results showing no effect of COC (at a dose of 5 mg/kg) on SI disagree 
with a recent study by Šlamberová et al. (2015), who revealed a dose dependent effect of COC 
on social behaviour, with higher doses (2.5, 5 and 10 mg/kg) decreasing SI and lower doses (1 
mg/kg) having no effect. 
Our results showed that acute MOR treatment decreased both total time spent in SI as 
well as the occurrence of SI in both prenatally exposed groups of animals. Additionally, MOR 
also decreased locomotor activity, specifically it decreased both time spent in locomotion as 
well as the occurrence of rearing. MOR has been previously shown to inhibit locomotor activity 
in a dose dependent manner (Babbini and Davis 1972). This inhibiting effect on locomotion 
also agrees with our present results from the Laboras test. One could conclude that decreased 
social behaviour in animals was as a consequence of decreased locomotor activity. However, 
MOR strongly decreased not only total time and occurrence of SI, but also particular patterns 
of SI, specifically, mutual sniffing, following, and climbing over time. Therefore, it seems that 
MOR ability to reduce social-interactions was independent of its locomotor-inhibiting effect. 
Our results are also in agreement with a study by Herman and Panksepp (1978) that showed a 
separation distress in infant guinea pigs by demonstrating increased vocalization even after low 
doses of MOR (0.75 mg/kg). 
Our results from SIT did not show any effect relative to treatment with THC regarding 
total time spent in SI, which is in contrast to results of O'Shea et al. (2006). The discrepancy 




decreased SI after chronic treatment with the cannabinoid receptor agonist (CP 55 940) 
following a 28-day drug-free period before the test. Additionally, Schneider et al. (2008) 
demonstrated that acute cannabinoid administration induced more deficits in social behaviour 
of pubertal rats than in mature rats. Non-social activities were also not affected by THC 
treatment, which corresponds to our results from the Laboras test; however, it does not agree 
with other that have shown that THC decreases locomotor activity (Hernandez-Tristan et al. 
2000, Schramm-Sapyta et al. 2007). Additionally, in our present study, the occurrence of 
following and climbing over, which are taken as parameters of social behaviour requiring motor 
activity, were increased after THC treatment. We suggest that the discrepancy might have been 
cause by a different dose of THC used in our study (2 mg/kg) and the study of Schramm-Sapyta 
et al. (2007), which was 5 mg/kg. 
9.4 Effect of drugs on the anxiety in the Elevated Plus Maze test 
The EPM test was used to examine the effect of acute drug treatment on anxiogenic and 
anxiolytic behaviour, as well as locomotor activity of prenatally MA-exposed adult male and 
female rats. Our results can be summarized as follows: females treated with MA demonstrated 
increased time spent in the OA and decreased time spent in the CA compared to MA-treated 
males. Both, AMP and COC treatment increased time spent in the OA in females compared to 
drug-treated males and saline-treated females and also decreased the number of pSAP. These 
results indicate an anxiolytic effect of MA, AMP, and COC, which was only seen in the groups 
of drug-treated females. MDMA increased time spent in the CA in females compared to saline-
treated females, which indicates an anxiogenic effect of MDMA shown on females. 
Anxiogenic-like behaviour was also seen after MOR and THC treatment in females as well as 
in males; this was demonstrated by increased time spent in the CA and the increased number of 
pSAP.  
It should be noted that studies testing the effect of psychostimulants on anxiety display 
inconsistent findings. In the EPM test, acute and chronic exposure to psychostimulants has been 
shown to have both, anxiogenic (Biala and Kruk 2007, Hayase et al. 2005, Pometlová et al. 
2012) and anxiolytic effects (Schutová et al. 2010). The disagreements found between different 
studies might have been caused by different tests settings, as well as by different gender of the 
animal model used. For example, in the study of Hayase et al. (2005) anxiety-related behaviour 
was observed in males at 3- and 5-day time points after a single dose of MA (4 mg/kg), which 
was observed to disappear after 10 days. Only the study by Schutová et al. (2010) used a similar 




the behaviour of male rats. They found that MA (1 mg/kg) decreased anxiety in prenatally MA-
exposed males by increasing time spent in the OA, which is in contrast to our results that 
showed no effect of MA (as well as AMP and COC) on males (Schutová et al. 2010). Our 
explanation of these inconsistencies is as follows: in the present study MA was administrated 
45 minutes prior to the test, while in the study of Schutová et al. (2010) it was 30 minutes prior 
to the test. The time of the injection in our study was chosen on the basis of the study of a study 
by Rambousek et al. (2014) showing that MA levels in the brain of adult rats peak from 45 min 
to 1 h after MA administration. Since testing did not start until 45 minutes after the drug was 
administrated, we could not see if there was any drug effect in the male rats 30 minutes after 
drug administration. Moreover, a study by Rambousek et al. (2014) also demonstrated that 
females have higher levels of plasma and brain MA after a single dose of MA (1 mg/kg) 
compared to males. Because we did not see any effect of MA 45 minutes after drug 
administration in males, we can speculate, that males are more sensitive to the anxiolytic-like 
effect at lower brain levels of MA.  In the present study animals were habituated to the 
experimenter 3 days prior to testing to reduce stress. Therefore, another explanation might be 
nothing more than different stress reactivity of females compared to males. Although no 
differences in the brain level of COC in rats after an acute COC injection have been found, 
females react more intensively to COC administration than males (Carroll et al. 2004). 
Additionally, locomotion was increased after MA, AMP, and COC treatment, but only in 
females compared to drug-treated males, which, again, supports the previous results of higher 
sensitivity of females to the psychomotor-stimulating effects of these drugs (as previously 
mentioned). As a result we cannot completely exclude that the anxiolytic effect seen only in 
females after MA, AMP, and COC treatment was not a consequence of the psychomotor-
stimulating effect of these drugs.   
Females after MDMA treatment (5 mg/kg) demonstrated increased time spent in the 
CA, which indicates an anxiogenic effect of MDMA. Similarly to other psychostimulants, both, 
the anxiogenic and anxiolytic effects of MDMA have been previously shown after acute 
treatment. A dose-dependent effect was found in the study by Navarro and Maldonado (2002) 
in rats, with 8 mg/kg producing an anxiogenic-like effect. On the other hand, the anxiolytic 
effect of MDMA (at a dose of 5 mg/kg) was found in the study of Daza-Losada et al. (2009) on 
mice. In the study by Páleníček et al. (2005) the anxiolytic-like effect of MDMA (at a dose of 
10 mg/kg) was found, in both, females and males. Moreover, MDMA increased the number of 
all arm entries by both genders, indicating that MDMA has a locomotor-stimulating effect, 




Páleníček et al. (2005) we did not find females to be more sensitive than males to MDMA-
induced locomotion. However, in their study they used a different test model (activity cage and 
open field) for testing locomotor activity. The decreased rearing movement after MDMA was 
shown in both sexes, which agrees with a study by Spanos and Yamamoto (1989). It has been 
suggested that the decreased rearing is based on co-activation of the DA and 5-HT systems after 
MDMA treatment.  
In both, females and males, MOR treatment increased the time spent in the CA, but did 
not significantly affect time spent in the OA and increased the number of SAP. These data 
indicate the anxiogenic effect of MOR, which is in contrast to results from a study by Zarrindast 
et al. (2005) that showed the anxiolytic effect. Discrepancies might have been caused by 
different dose regimens and drug administration used in our study and studies of others. While 
Zhang and Schulteis (2008) used MOR at a dose of 10 mg/kg s. c. (compared to our study 5 
mg/kg s.c.), while Zarrindast et al. (2005) administrated 3, 6, and 9 mg/kg, intraperitoneally. 
Moreover, in the study of Zhang and Schulteis (2008) MOR was administered 2 hours, prior, 
while in our study it was given 45 minutes prior to the EPM test. As far as the drug effect on 
locomotion was concerned, we found that MOR decreased locomotion in males, and did not 
have any effect on females. This locomotor-inhibiting effect corresponds with our results from 
the Laboras test as well as the SIT; however, it disagrees with results from a study by Babbini 
and Davis (1972). Similarly to MOR, THC treatment increased time spent in the CA and 
decreased the number of all arm entries, comparable in both genders, which indicates an 
anxiogenic and locomotor-inhibiting effect of acute THC treatment. The increased anxiety and 
decreased locomotion showed in our study agrees with the results of the study by Arevalo et al. 
(2001) that showed an aversion, by rats, to the open arms of the EPM 30 minutes after treatment 
with a cannabinoid antagonist (CP 55 940). 
Rogers and Johnson (1995) recommended incorporating the protected SAP as a 
parameter of the anxiogenic-like behaviour. Higher numbers on pSAP indicates more 
anxiogenic-like behaviour (Espejo 1997, Rodgers and Johnson 1995). Even when using this 
specific parameter, our results from the EPM test were supported. Specifically, the decreased 
number of pSAP after AMP and COC confirmed the anxiolytic effect, while the increased 
number of pSAP after MOR and THC confirmed the anxiogenic effect of these drugs.  
Additionally, the validity of SIT and EPM for measuring anxiety has been the previous 
topic of several discussions (File and Hyde 1978, Rodgers et al. 1997) based on the different 
results coming from these tests. These two tests have been suggested for examining different 




places, the SIT examines the emotional response to an unknown animal (Rodgers et al. 1997). 
However, the comparison of these two tests regarding their validity in measuring anxiety goes 
beyond the scope of our discussion.  
9.5 Effect of drugs on spatial learning in the Morris Water Maze test 
In the MWM test was used to examine the effects of chronic drug treatment on spatial 
learning, as well as on locomotor activity of prenatally MA-exposed adult male and female rats. 
Our results are as follows. Firstly, data from the Place Navigation test showed that females with 
chronic MA treatment in adulthood swam longer distances and demonstrated longer latencies 
to reach the hidden platform, which indicates reduced learning abilities. In our present study 
we only tested females relative to the effect of chronic MA treatment, as we wanted to extend 
the previously published data reported in a study by Schutová et al. (2009). They showed 
prolonged trajectories as well as changes in swimming strategies after MA treatment in males 
in the same test setup. Furthermore, we found that females with MA treatment, compared to 
males from a study by Schutová et al. (2009), also demonstrated increased search error, which 
is, according to some authors, a better reflectance of the accuracy of spatial learning than 
latency, since this parameter describes the total distance to the platform during the trials. Two 
animals may have similar latencies although the lengths of their swimming paths might differ 
markedly. While one animal searches for the platform in the quadrant, in which the platform is 
placed, the other may search more within the opposite quadrant (Gallagher et al. 2015). From 
these results, we might suggest, that the effect of MA treatment has a more potential effect on 
females than on males. Unexpectedly, in the Probe test, we found that saline- and MA-treated 
females had comparable spatial abilities, since they did not differ in any of the parameters. This 
type of test, in which the animal swims without the platform being present, provides information 
about memory retention after the position of the platform had been learned by the animal. 
Therefore, it seems that even though the MA treatment reduced learning abilities, it did not 
have any additional effect on memory recall, which was also supported by the results on the 
Memory test, which also showed no effects of MA treatment.  
Both, AMP and COC treatment affected female rats’ performance in the MWM (by 
increasing latencies, distances travelled and search errors). Moreover, the effect of AMP and 
COC was not apparent in males. Comparably, MA, AMP, and COC also did not affect any 
parameters of the Probe test. However, the effect of AMP and COC treatment on adult females 
was shown on the Memory Recall test, which was performed on the last day of testing. 




Probe test, AMP and COC treatment impaired the ability of female rats to recall the spatial map 
formed during the learning phase. Our COC results are in agreement with a study by Mendez 
et al. (2008) who also showed long-term cognitive deficits in rats, which persisted even 3 
months after chronic COC treatment. With respect to our results, there are two thought-
provoking outcomes. First, it seems that chronic AMP and COC has more long-term effects on 
spatial learning abilities than chronic MA, since there was still some memory impairment seen 
on the last day of testing. Second, females tend to be more sensitive to the memory-impairing 
effects of AMP and COC. Additionally, there was an interesting gender difference in spatial 
learning abilities after MDMA treatment. Female rats demonstrated decreased performance on 
the Place Navigation test, which indicates reduced learning, as well as reduced performance on 
the Probe test and the Memory test. On the other hand, male rats did not have any impairments 
in learning skills over the course of the Learning test; however, the Probe test and even more 
so the Memory test revealed some memory deficiencies in our test animals. Our results are in 
agreement with studies that showed learning impairments after chronic MDMA treatment 
(Morley et al. 2001), as well as long-term neurotoxicological effects (e.g. depletion of 5-HT), 
particularly in the hippocampus, a brain region which plays an important role in spatial learning 
(Aguirre et al. 1997). 
We suggest that the differences in the drug effects on learning and memory recall found 
in the MWM are probably based on gender variations in neurotransmitter systems shown in 
other studies (Robinson et al. 1980), and on the fact, that these systems have been shown to be 
affected by chronic treatment with these drugs in diverse ways (Baumann et al. 2007, Wagner 
et al. 1979, Wilson et al. 1992). Although, the neurotoxic effect of chronic treatment with these 
drugs on the different neurotransmitter systems have been shown, the consequences of long-
term drug use on the cognitive functions still remain unexplained.  
There was also a significant effect of MOR and THC treatment on the learning abilities 
shown on the Place Navigation test. Females after MOR and THC swam longer distances with 
increased latency and search error. Moreover, impaired learning skills were revealed on both, 
the Probe test and the Memory test. To best of our knowledge, there is no study investigating 
gender differences on performance in the MWM after chronic MOR treatment. Some studies 
have demonstrated that long-term administration of MOR (Pu et al. 2002) leads to reduction in 
the capacity of male rats' hippocampal LTP, which is a neural mechanism underlying learning 
and memory. The same authors (Pu et al. 2002) reported impaired learning in the MWM in 
parallel with a reduction of hippocampal long-term potentiation after chronic MOR treatment. 




memory in adult rats accompanied by reduced levels of markers of neuroplasticity in the 
hippocampus (Rubino et al. 2009). Another study showed a dose-dependent relationship 
regarding the effect of THC on spatial learning in females (Cha et al. 2007).  
As far as drug treatment effect on the speed of swimming is concerned, we did not find 
any effect of MA, AMP, and COC treatment in either females or males. Although these results 
do not correspond with our results from the Laboras test, which showed increased locomotion 
after AMP treatment, it should be noted that in the MWM test, animals were tested 24 hours 
after drug administration, when the acute locomotor-stimulating effect might have been 
diminished. On the hand, chronic MDMA, MOR, and THC treatment increased speed of 
swimming in females. It should not be marginalise that some authors have suggested that 
increased speed of swimming in the MWM is positively correlated to an increased motivation 
of an animal to find a hidden platform (Lubbers et al. 2007).  
Another explanation for our results showing learning impairments after all drug 
treatments, but only in females, might be based on different stress-coping mechanisms if 
females relative to males. It has been reported in a study by Handa et al. (1994) that the 
hypothalamic-pituitary axis in females reacts more robustly to stress, which is in part due to 
oestrogen having an enhancing effect on it. Moreover, stress conditions in the MWM were 
shown to increase corticosterone in males (Akirav et al. 2001), the level which was shown to 
have decreased after neonatal MA treatment in males but not in females after MWM testing 
(Williams et al. 2003). Therefore, it seems that increased levels of corticosterone combined 
with the drug treatment might be responsible for disturbances in spatial learning in females.  
 
10. THE EFFECT OF PRENATAL MA EXPOSURE 
The effect of prenatal MA-exposure based on the Laboras locomotor activity test can be 
summarized as follows: Neither males nor females demonstrated changes in any of the 
parameters of locomotor activity. Our data are in agreement with a study by Schutová et al. 
(2010) that showed no effect of prenatal MA on males tested in the Open-field test in adulthood. 
However, the lack of effect prenatal MA exposure on the spontaneous locomotor activity in 
females demonstrated in our study is in contrast to a study by Schutová et al. (2013) that showed 
prenatal MA exposure decreased locomotion and velocity of females on the Laboras test. 
Although there are studies showing some impairments of the sensorimotor development in pups 




support previous suggestions that these changes do not persist into adulthood. Moreover, female 
behaviour did not differ from male behaviour after prenatal MA exposure, although, it was 
reported in a study by Engele et al. (1989) that the development of the mesolimbic 
dopaminergic system in female and male rats displays some gender variances and might be 
affected differently in response to prenatal drug exposure.  
Our results from the SIT did not reveal any effect of prenatal MA exposure on social 
behaviour, or non-social behaviour. There was also no effect of prenatal MA exposure on 
anxiogenic, anxiolytic, and locomotor behaviour in EPM, which is in agreement with previous 
studies of Hrubá et al. (2012) and Schutová et al. (2010). From these results we suggest that 
prenatal MA exposure does not cause such changes in the developing brain of rats that would 
persist into adulthood as a reflexive anxiety-related behaviour. We also did not see any effect 
of prenatal MA exposure on learning abilities and memory recall in females and males tested 
in the MWM. This result is in agreement with previously published study by Schutová et al. 
(2009), however it disagrees with the results of other studies that showed prenatal MA reducing 
spatial learning abilities (Šlamberová et al. 2005).  
Since several forms of behaviours were tested in this study, and no effect of prenatal 
MA exposure was found in any of them, we conclude that prenatal MA exposure probably does 
not impair the development of baseline neurotransmission pathways involved in these forms of 
behaviour. However, the effect of prenatal MA exposure on different forms of behaviour, tested 
in adulthood, was not central focus of this study and therefore is we will consider further 
discussion to be beyond the scope.  
 
11. THE EFFECT OF GONADAL HORMONES 
As far as gender differences effecting locomotor activity are concerned, our results from 
the Laboras test demonstrated that males were generally less active than females, and females 
in P/E were more active than females in M/D. Additionally, similar results were found on the 
EPM and the CPP tests, which was shown by increase entries into all arm on the EPM test, and 
by increase entries into chambers on the CPP test. Similar gender differences in locomotor 
activity were also found in others studies (Bisagno et al. 2003, Hrubá et al. 2012). These gender 
differences in the locomotor activity are probably based on DA metabolism in the striatum, 




(1999) suggested that a greater behavioural response in oestrus was related to increased 
stimulation of the striatal dopaminergic system by gonadal hormones.   
Our results from the EPM test demonstrated, that females were generally less anxious 
than males, especially females in proestrus spent more time in the OA and less time in the CA. 
Decreased anxiety in females in proestrus was not a surprising result, since there are studies 
reporting that ovarian hormones play an important role, both organizationally and 
activationally, relative to plus-maze behaviours in females (Mora et al. 1996, Zimmerberg and 
Farley 1993). Furthermore, OVX females have been shown to exhibit anxiogenic behaviour, 
which was attenuated by the oestradiol treatment (Mora et al. 1996). Another possible 
explanation of our results might be based on differences in ontogenesis of anxiogenic behaviour 
found in a study by Imhof et al. (1993). They showed gender differences in EPM performance 
in rats at 60 and 120 days. Female rats demonstrated decreased time spent in the OA at the age 
of 120 days, whereas in males it happened around the age of 90 days. Animals tested in our 
study were between 60 and 90 days of age.  
Results from the MWM did not show any differences in learning abilities between males 
and females as the Place Navigation test proceeded. However, the Memory test and the Probe 
test showed that males were able to memorize the location of the platform more effectively than 
females, which is in agreement with a study by Perrot-Sinal et al. (1996). Regarding previously 
discussed gender differences in the stress reactivity of females, females in a study by Perrot-
Sinal et al. (1996) demonstrated increased anxiety and aversion-related tigmotaxis behaviour 
in the MWM compared to males. This behaviour was diminished after familiarization with 
certain aspects of the water-maze during the pre-training period. There have also been other 
MWM studies that showed that male animals have an advantage in spatial learning, which were 


















IV. GENERAL CONCLUSIONS 
Results from our study can be summarized as follows: 
 
1) As far as the effect of prenatal MA exposure on sensitivity to drug treatment in 
adulthood is concerned: 
a) The CPP test: prenatal MA exposure did not sensitise animals to the preference of an 
environment associated with either MA, or drugs with the same mechanism of action to 
MA (AMP, COC, MDMA), or drugs with different mechanism of action to MA (MOR, 
THC). 
b) The Laboras test: prenatal MA exposure sensitised animals to the locomotor-
stimulating effect of AMP in both sexes, and to the effect of COC and MDMA, but in 
females only. There was no cross-sensitisation found between prenatal MA exposure 
and drugs with different mechanisms of actions relative to MA (MOR and THC) 
administrated in adulthood. 
c) The SIT test: prenatal MA exposure sensitised animals to the social interaction-
decreasing effect of MA, AMP, and MDMA.  
d) The EPM test: prenatal MA exposure did not sensitise animals to the anxiogenic and 
anxiolytic effect of any of the drugs. 
e) The MWM test: prenatal MA exposure did not sensitise animals to the impairing effect 
of any of the drugs relative to spatial learning 
 
2) As far as sex differences on the effect of adult drug treatment is concerned:  
a) The CPP test:  
 There was an increase in time spent in the chamber associated with the drug in both, 
females and males, after MA conditioning. There was a decrease in time spent in the 
chamber associated with MDMA after conditioning in males, while females 
demonstrated an increase in time after MDMA conditioning. AMP and COC 
conditioning did not lead to preference for a chamber associated with these drugs. 
 Both, females and males, demonstrated an increase in the time spent in the chamber 
associated with MOR and no preference for a chamber associated with THC. 
b) The Laboras test: 
 Both, females and males, after AMP and MDMA demonstrated increased time spent in 




decreased speed of movement, but only in females. Females, but not males, after COC 
demonstrated increased locomotion.  
 Both females and males, after MOR, demonstrated decreased locomotion. THC did not 
influence locomotor activity in males, while it increased the speed of movement in 
females.  
c) The SIT test 
 Only MA, AMP, and MDMA decreased total time spent in social interactions in males. 
MA did not influence locomotion, while AMP, COC, and MDMA increased 
locomotion. MA, AMP, and COC increased rearing; however, MDMA decreased 
rearing.   
 In males, MOR decreased social interactions (time and occurrence) as well as decreased 
locomotion and rearing. THC did not influence social interactions and locomotion. 
d) The EPM test 
 MA, AMP, and COC showed anxiolytic and locomotor-stimulating effects, but only in 
females. MDMA demonstrated anxiogenic and locomotor-stimulating effects, in 
females.  
 Both THC and MOR demonstrated anxiogenic and locomotor-inhibiting effects in both 
genders 
e) The MWM test 
 Chronic treatment with MA reduced spatial learning, in females; however, it did not 
have any effect on memory recall. Chronic treatment with AMP and COC reduced both 
learning and memory recall only in females. MDMA reduced both learning and memory 
recall in females, and reduced memory in males.  
 Chronic treatment with THC and MOR reduced learning and memory in females.  
 The speed of swimming was not affected by chronic treatment with MA, AMP, and 
COC. On the other hand, chronic treatment with MDMA, MOR, and THC increased 
speed of swimming in females.  
Results from our study showed that prenatal MA (at a dose of 5 mg/kg) administrated 
to mothers during the entire gestational period can sensitise their offspring to the application of 
other drugs in adulthood. Specifically, it seems that animals after MA exposure in utero 
demonstrated some kind of locomotor augmentation when exposed to psychostimulants (COC, 
AMP, and MDMA) later in adulthood. Our results suggest that exposure to MA during 




greater responses to the psychostimulant effects of drugs administrated in adulthood. However, 
increased locomotor reactions were not seen after application of any of the tested drugs, 
especially, drugs with different mechanism of action than MA (e.g. MOR, THC). Furthermore, 
exposure to MA during the gestational period did not cause any changes in the brains of 
offspring, which would predispose them to increased drug seeking later in life. In addition, 
other test situations did not reveal any sensitising effect of prenatal MA, apart from the test for 
social interactions, in which prenatally-MA exposed animals reacted more sensitively to the 
social-interaction decreasing effects of MA, AMP, and MDMA. 
These are interesting findings giving us new insight into the problem of induced- 
sensitisation after prenatal MA exposure. It should be emphasize that the drugs used to test the 
sensitising effects after prenatal MA exposure, were all drugs having a similar mechanism of 
action to MA, and that this sensitising effect was not seen in all test situations. That is why we 
cannot simply conclude that prenatal MA exposure leads to an increase in sensitivity to different 
drugs of abuse, and thus causes development of general drug addiction. 
Our study also demonstrated gender differences in the effect of drugs on various forms 
of behaviour, like drug-seeking behaviour, anxiety-related behaviour, as well as cognitive 
functions. It appears that gonadal hormones in females play an important role in overall 
response to drug. However, the range and form of behaviours disturbances rely on the type of 
drug and on its mechanism of action. It is clear, that the interactions between gonadal hormones 
and the effect of drugs of abuse on neurotransmitter systems have a greater effect on behavioural 
sensitisation in females than in males.  
Despite numerous studies investigating sensitisation as a complex process arising from 
different cellular changes in many brain regions, the neural basis of it is not fully understood. 
Moreover, there are increasing numbers of preclinical studies focusing on long-lasting changes 
in motivational behaviours or the function of brain reward circuits in animals during gestational 
drug exposure. Since MA is still one of the most accessible drugs in the Czech Republic, and 
also in many cases, the first drug of choice for many drug-addicted pregnant women, we were 
faced with the question of whether children born to mothers, who abused MA during pregnancy, 
have an increased risk of substance abuse or other addictive behaviours as they grew up and 
entered adulthood. The question is particularly pertinent since changes developed in prenatal 
life, in many cases, persist until adulthood. This can consequently impair healthy development 
and future social inclusion of the children as they mature. Since clinical studies are difficult to 
perform, developing a testable hypothesis through preclinical research can potentially increase 




in prenatally MA-exposed offspring. Our findings are that although the offspring of the MA-
addicted mothers have altered sensitivity to various drugs in adulthood, they do not display 
increased active drug-seeking behaviour. In an anthropomorphic language, results from our 
study show that children of mothers who used MA during pregnancy might have an increased 
reaction to other drugs when they encounter them later in life. This situation by itself might 
intensify their interest in drugs. On the other hand, prenatal MA might not cause such changes 
that would make an individual more prone to drug search as an adult. In addition, the findings 
that prenatally MA exposed females are more vulnerable than males when encountering 
different drugs later in life, need further investigation. 
We hope that our results will lead to a better understanding of the factors, which 
contribute to prenatal MA exposure altering the brain in terms of behaviour, and how these 
factors enhance the risk for addiction. Our results offer new insights into drug addiction from 
the perspective of children of women, who abused drugs during pregnancy, and also suggest 
new directions for research into drug addiction. Hopefully, these new insights will contribute 
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